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The objective of this study was to develop copper based anti-inflammatory 
agents for the treatment of inflammation associated with Rheumatoid 
Arthritis. 
Four low molecular ligands, N,Nt-di(aminoethylene)-2,6-pyridine 
dicarbonylamine (PrDH), Bis-(N,N-dimethylethyl)-2,6-pyridinedicarboxamide 
(PrDM), N,N'-bis[2(2-pyridyl)-methyl]pyridine-2,6-dicarboxamide (PrDPr) and 
3,5-bis[(aminoethyl)ethanediamide]-4-oxahexacyclo-dodecane (PCUA) were 
designed and synthesised. The formation constants of these ligands with H+, 
Cu2+, Niz+, Znz+ and Caz+ were determined potentiometrically at 25°C and 
0.15 mol dm-3 Na+Cr. The Cu(II) formed relatively more stable complexes 
than other three metal ions. 
The structures of the different Cu(II) species formed with these ligands were 
investigated using nuclear magnetic resonance(NMR), infrared (IR) 
spectroscopy, ultraviolet-visible (UV-visible) spectroscopy as well as molecular 
mechanics calculations. For the NMR spectroscopy, results showed that the 
central pyridyl nitrogen and amide nitrogen(s) as well as the terminal 
amino/pyridyl groups coordinate to the Cu(II) ion in solution. The IR results 
indicated that an amide nitrogen is coordinated to the Cu(II). The UV-visible 
study gave the smooth deconvoluted spectra of the individual species for the 
Cu(II)-PrDH, Cu(II)-PrDM and Cu(II)-PrDPr systems in support of the 
potentiometric results. The three studied ligands form tetragonally distorted 
octahedral MLH-l and MLH-z species with Cu(II). The molecular mechanics 
was used to calculate the internal strain energies of the different possible 
geometries of related complex species. A comparison of these energies was 











The speciation modelling of Cu(II) using a computer model of blood plasma 
indicated that the in vivo Zn(II) and Ca(II) are good competitors of Cu(II) for 
PrDH, PrDM and PCUA whereas PrDPr is relatively selective for Cu(II). The 
1C50 values recorded for the Cu(II) complexes suggest that they are poor 
mimics of the Cu-Zn-SOD enzyme. The study also considered the 
determination of the octanol-water partition coefficients (logPoct!aq) as a 
measure of hydrophobicity. It was observed that the ligand system with bulky 
groups as well as these forming neutral complex species had an enhanced 
extraction into the organic phase. 
The in vivo verification of the modelling results was carried out by performing 
bio-distribution and dermal absorption studies on mice using radioactive 
64Cu(II) as a tracer. The biodistribution results showed that the 
[64Cu]Cu(II)-PrDH, [64Cu]Cu(II)-PrDM, [64Cu]Cu(II)-PCUA and 
[64Cu]Cu(II)-PrDPr complexes had improved absorption and retention over 24 
hours in the body. The dermal absorption results also showed that at least 3 
%dose of the applied dose on the enclosed skin was absorbed over a period 
of 24 hours. 
Overall, these results are encouraging and merit further evaluation for the 
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-logarithm of the overall stability constant 
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-ethylenediamine tetraacetic acid 
-Rheumatoid Arthritis 
-non-steroidal anti-inflammatory drugs 
-disease modifying anti-rheumatic drugs 











np -number of parameters being optimised 
ne -the total number of electrodes 
wnq -the weight of the qth residual at the nth point 
Ynq -electrode emf of qth residual at dh point 
RH -Hamiltonian R-factor 
Rlim H -Hamiltonian R limit 
!J.o or 10Dq -ligand field splitting 
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10 -intensity of incident radiation 
I -intensity of transmitted radiation 
£ -the molar absorption coefficient 
I,max -frequency of maximum absorption 
Utotal -total strain energy 
I Eb -total bond deformation energy 
I Ef} -total valence angle deformation energy 
I Eli -total torsional (or dihedral) deformation energy 
I Enb -total non-bonded (van der Waals) interaction energy 
Kb -force constant or spring strength 
ro -ideal bond length 
K" -strength of the spring holding the angle at its ideal value eo 
Kti -height of the barrier to rotation about the torsion angle ¢ljkl 
m -periodicity 
¢offset -offset of the minimum energy from a staggered arrangement. 
1C50 -concentration of drug required to reduce diformazan formation 
by 50% 
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-Evaluation of Constituent Concentrations in Large Equilibrium 
Systems 
-plasma mobilization index 
-Equilibrium Simulation for Titration Analysis 
-task to calculate objective function 
-task to calculate the complex formation function 
-complex formation function 
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-task to calculate the speciation as a function of pH 
-task for initial estimates of formation constants values 
-potassium hydrogen phthalate 
-tetra methyl silane 



















DECLARATION ...................................................................................................... i 
ACKNOWLEDGEMENT .......................................................................................... ii 
COI\lFERENCE ...................................................................................................... iii 
ABSTRACT .......................................................................................................... iv 
LIST OF SyMBOLS ............................................................................................. vi 
LIST OF ABBREVIATIONS ................................................................................ vii 
CHAPTER 1: INTRODUCTION 
1.1 Rheumatoid Arthritis ................................................................................ 1 
1.2 Therapy for Rheumatoid Arthritis ........................................................... .3 
1.2.1 Non-steroidal anti-inflammatory drugs .......................................... 3 
1.2.2 Disease modifying anti-rheumatic drugs ...................................... .4 
1.2.3 Glucocoticoids ................................................................................. 5 
1.3 The involvement of copper ...................................................................... 6 
1.3.1 Possible modes of action of copper(II) complexes ........................ 7 
1.4 Designing Cu(II) complexes as anti-inflammatory agents ...................... 9 
1.5 Aim and objectives of this study ............................................................ ll 
References 
CHAPTER 2: LIGAND DESIGN AND SYNTHESIS 
2.1 Introduction .......................................................................................... 16 
2.2 Ligand selection ..................................................................................... 16 
2.3 Synthesis ................................................................................................ 20 
2.3.1 Preparation of PrDH ..................................................................... 21 
2.3.2 Preparation of PrDM ..................................................................... 22 
2.3.3 Preparation of PrDPr. ................................................................... 23 












CHAPTER 3: GLASS ELECTRODE POTENTIOMETRY 
3.1 Introduction ........................................................................................... 28 
3.2 -rheory .................................................................................................... 29 
3.3 Equilibrium Simulation for Titration Analysis ........................................ .33 
3.3.1 The objective function ................................................................ 34 
3.3.2 Formation and deprotonation functions ...................................... 35 
3.3.3 Standard deviation and Hamiltonian R-factor. ............................ 38 
3.4 Experimental. ......................................................................................... 39 
3.4.1 Equipment. ................................................................................... 39 
3.4.2 Preparation and standardisation of solutions ............................. 39 
3.4.3 Titration and data analysis .......................................................... .40 
3.5 Results and discussion .......................................................................... .42 
3.5.1 Protonation formation function ................................................... .42 
3.5.1.1 H+-[PrDH] system .......................................................... .42 
3.5.1.2 H+ -[PrDM] system ......................................................... .43 
3.5.1.3 H+ -[PrDPr] system ......................................................... .44 
3.5.1.4 Discussion - Protonation ................................................ .45 
3.5.2 Complex formation and deprotonation functions ........................ 47 
3.5.2.1 M2+ -[PrDH] system ........................................................ .48 
3.5.2.2 M2+ -[PrOM] system ....................................................... .54 
3.5.2.3 M2+ -[PrDPr] system ........................................................ 60 
3.5.2.4 Discussion - Complexation ............................................. 65 
References 
CHAPTER 4: SPECTROSCOPY AND MOLECULAR MODELLING 
4.1 Nuclear magnetic resonance .................................................................. 78 
4.1.1 Introduction .................................................................................. 78 
4.1.2 Experimental. ............................................................................... 78 
4.1.3 Results and discussion ................................................................ 79 
4.1.3.1 Cu(II)-PrDH system ........................................................ 79 











4.1.3.3 Cu(II)-PrDPr system ....................................................... 84 
4.2 Infrared spectroscopy ............................................................................ 87 
4.2.1 Introduction .................................................................................. 87 
4.2.2 ExperimentaL ................................................................................ 88 
4.2.3 Results and discussion ................................................................. 88 
4.2.3.1 Cu(II)-L systems ............................................................. 88 
4.3 UV-visible spectroscopy ......................................................................... 93 
4.3.1 Introduction .................................................................................. 93 
4.3.2 Electronic spectra of metal complexes ........................................ 93 
4.3.2.1 Copper complexes .......................................................... 94 
4.3.3 Data analysis ................................................................................ 96 
4.3.4 Experimental ................................................................................. 98 
4.3.5 Results and discussion ................................................................. 99 
4.3.5.1 Cu(II)-L systems ............................................................ 99 
4.4 Molecular mechanics ............................................................................ 106 
4.4.1 Introduction ................................................................................ 106 
4.4.2 Theory ........................................................................................ 107 
4.4.3 Simulations ................................................................................. 109 
4.4.4 Results and discussion ............................................................... 111 
4.4.5 Discussion - Proposed structures ............................................... 117 
References 
CHAPTER 5: BIO-MODELLING AND ANIMAL EXPERIMRNTS 
5.1 The blood plasma model .................................................................... 123 
5.1.1 Introduction ............................................................................... 123 
5.1.2 Blood plasma simulation ............................................................ 125 
5.2 Superoxide dismutase mimetic activity studies ................................... 128 
5.2.1 Introduction ............................................................................... 128 
5.2.2 Determination of Cu(II)-L SOD mimetic activity ...................... 129 
5.2.3 Experimental. ........................................................................... 130 
5.2.4 Results and discussion ............................................................. 131 











5.3 Octanol/water partition coeffiecients ................................................... 135 
5.3.1 Introduction ............................................................................... 135 
5.3.2 Experimental.. ........................................................................... 136 
5.3.3 Results and discussion .............................................................. 137 
5.3.3.1 Cu(II)-L systems ......................................................... 137 
5.4 Bio-distribution studies ......................................................................... 141 
5.4.1 Introduction ................................................................................ 141 
5.4.2 Experimental .............................................................................. 143 
5.4.3 Results and discussion ............................................................... 145 
5.5 Dermal absorption studies ................................................................... 153 
5.5.1 Introduction ................................................................................ 154 
5.5.2 Experimental ............................................................................. 154 
5.5.3 Results and discussion.................... ...... .................................. 155 
References 
CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION 
APPENDIX ............................................................................................................. i 
List of Figures ............................................................................................. i 





















1.1 RHEUMATOID ARTHRITIS 
Rheumatoid Arthrtis (RA) is a chronic, debilitating disease for which there is 
no cure. 1,2 It is characterized by joint pain and swelling, joint destruction and 
pannus formation. 2,3 RA remains a medical challenge because it affects about 
one percent of the general population4 and so far the exact cause of the 
disease is still not known. However, it is known that RA is an autoimmune 
disease.2 The body's natural immune system does not operate as it should 
resulting in the immune system attacking healthy joint tissue and causing 
inflammation and subsequent joint damage. 
RA is properly considered a disease of the joint. However, the inflammation 
response is a normal and essential response of the body to a harmful stimulus 
and may vary from a localized reaction in an affected tissue or joint to a more 
generalized whole-body reaction. 5 At the early stages of inflammation in RA 
perivascular aggregates of lymphocytes in the synovium are seen along with 
increased thickness of the synovial lining layer. 3 Chronic inflammation results 
in the destruction of normal connective tissue due to the activities of catalytic 
enzymes and cytokines. This destruction is due to activation of immune 
response, the release of hydrolytic enzymes, for example; collagenases, 
proteases, gelatinases, matrilysin, and the subsequent degradation of 
collagen and other extra-cellular components found in the body joints and 
connective tissues. 5 The situation of a joint affected by RA is well represented 
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Figure 1.2: Schematic representation of a jOint affected by Rheumatoid Arthritis 
Further more, it is important to recognise that RA can exhibit a variety of 
extra-articular manifestations. These manifestations clearly show that RA has 
features of systemic disease capable of involving a variety of major organ 











show that within rheumatoid synovium, there is hyperplasia of synovial lining 
cells and development of an extensive network of new blood vessels.4 
Despite many decades of investigation, the etiology of RA remains unknown 
and its specific pathogenic mechanism is poorly understood. 3,4 However, the 
diagnosis is based on the clinical manifestations or findings. The symptoms 
associated with the disease can be alleviated by the use of anti-inflammatory 
drugs. 
1.2 THERAPY FOR RHEUMATOID ARTHRITIS 
The uses of drug therapy for RA are the relief of pain, the inhibition of 
inflammation and the restoration of normal immune mechanisms.? Highly 
effective drug treatments exist but early treatment is critical for relief of pain, 
reducing inflammation, stopping or slowing jOint damage, and improving 
patient function and wellbeing. Ideally, a treatment should be efficacious, free 
of side effects, affordable and acceptable to the patient. Medication used in 
the treatment of RA can be divided into three categories; non-steroidal anti-
inflammatory drugs (NSAIDs), glucocoticoids and disease modifying anti-
rheumatic drugs (DMARDs). 
1.2.1 Non-steroidal anti-inflammatory drug 
NSAIDs help reduce joint pain, stiffness and swelling in RA but do not modify 
progression of the disease.3 Traditional examples of NSAIDs are Ibuprofen 
and Diclofenac sodium. These drugs including salicylates such as aspirin 
possess analgesic, antipyretic and anti-inflammatory properties. Although 
NSAIDs are effective fighters of both pain and inflammation, renal 
insufficiency and failure, gastrointestinal ulceration, bleeding or perforation, 
exacerbation of hypertension and congestive heart failure have become 










Because ulcers are potentially dangerous side effect of NSAIDs use, a new 
option of NSAIDs was recently brought to the market. These are called 
cyclooxygenase-2 (COX-2) inhibitors and are thought to function by inhibition 
of cyclooxygenase pathway of prostaglandin (PG) synthesis. 8 A variety of free 
radicals derived from molecular oxygen, including superoxide, hydroxyl, and 
perhydroxyl radicals, are involved in the biosynthesis of prostaglandins and 
can provoke cell injury. The NSAIDs may act as free radical scavengers 
(antioxidants) in addition to inhibiting the formation of free radicals in the 
arachidonic acid pathway.S,10 By impairing the activity of various mediators of 
inflammation such as bradykinins, prostaglandins and oxygen radicals, 
NSAIDs partially impair the final expression of inflammation. If patients with 
RA do not have a spontaneous remission with reasonable period of time, a 
slow-acting anti-rheumatic drug should be added to the continuing maximal 
NSAIDs therapy. 10 
1.2.2 Disease modifying anti-rheumatic drugs 
DMARDs apparently affect the rheumatoid disease process and the 
mechanism of action for this group of drugs is diverse. Included in this broad 
group are methotrexate, leflunomide, D-penicillamine, sulfasalazine, gold 
therapy, minocycline, azathioprine, hydroychloroquine (and other anti-
malarials) and cyclosporine. Although DMARDs actually stop disease 
progression before it causes irreparable joint damage, instant results should 
not be expected hence they are also called slow-acting anti-rheumatic drugs 
(SAARDs).3,4,6-11 The DMARDs differ from NSAIDs in their delayed onset of 
action and lack of analgesia. They appear to act more proximally on the 
inflammation process, perhaps on the immunologic initiators of tissue injury 
but without actually removing the basic cause of the disease. 1o 
Gold compounds are used most commonly for the treatment of RA although 
they have been used in the therapy of other inflammatory diseases as well. A 
potential mechanism of action of gold compounds in the treatment of erosive 










hyaluronidase which are capable of degrading connective tissue components.s 
Another effect of gold compounds is that they may protect against oxygen-
derived free radicals. Rash and mucous membrane ulcers are among the most 
common side effects in patients treated with gold compounds. 
Among the anti-malarials, hydroxychloroquine has been suggested to be as 
effective as gold, D-penicillamine and azathioprine. It is said to be probably 
the least toxic DMARD.I0 Chloroquine has been shown to decrease antigen 
processing and presentation by both macrophages and lymphoid dendritic 
cells.S,lO 
A widely used, effective DMARDs which was specifically developed for RA is 
leflunomide (Arava). It is a novel DMARD that inhibits pyrimidine synthesis 
and is approved for treatment of active RA. In addition, leflunomide has been 
shown to slow radiographic progression of RA. It can be used in combination 
with metrotrexate or in place of it.i2 
1.2.3 Glucocoticoids 
Glucocoticoids are sometimes referred to as corticosteroids or simply steroids. 
Therapeutic administration of these drugs produces rapid, potent and reliable 
suppression of inflammation. They have short-term effects on inflammation. 
The dramatic effects of cortisone and adrenocorticotropic hormone (ACTH) on 
the signs and symptoms of active RA were first reported by Hench and his 
associates in 1949.4 For many symptomatic rheumatic diseases, these drugs 
simply work very well but have too many side effects. The most feared 
complication in patients with RA have been the effects of steroids on the bone 
and gastrointestinal tract. 1O,12,13 
It should be mentioned that the presently available I'JSAIDs, DMARDs and 
glucocorticoids are rather unsatisfactory, being poorly effective and having 










effective and safer therapies for inflammatory diseases remains a major 
medical challenge. 
1.3 THE INVOLVEMENT OF COPPER 
IVletal ions playa vital role in a vast number of widely differing biological 
processes. These processes are quite specific in their metal ion requirements 
such that certain metal ions in specific oxidation states fulfil the necessary 
catalytiC or structural requirements. 14 The interrelationships between metal 
ions and binding substances in the body are so complex that disorders or 
disease involving the metal binding substances may result in the presence of 
high or low concentrations of metal ions compared with that normally 
present. A number of major diseases are associated with changes in 
concentration of the trace metal ions in certain tissues and body fluids. The 
role of metal ions in medicine can be considered for the following; a). metal 
poisoning, where excess metal is ingested, b). abnormalities resulting from 
breakdown of the body's own control system or failure of the metal ion 
control system and c). the diagnostic or therapeutic use of metal ions in the 
body. 
Of the metals that have been examined, copper appears to be most valuable 
pOinter to disease conditions. For infectious hepatitis, serum copper levels rise 
up to three times normal value due to an accumulation of ceruloplasmin. 
Other diseases associated with high copper concentrations in the blood are 
leukaemia, lymphomas, rheumatoid arthritis, psoriaSis, cirrhosis, rephritis and 
Hodgkins's disease. 14-18 
Biologically active oxidation states of copper are I, II and III, and these 
oxidation states are found in copper complexes that act to transport copper to 
body sites where it is required. The richest dietary sources of copper are 
animal liver, crustacean, shell fish, dried fruits, nuts and chocolate. 19 Dietary 











transported to the liver by the blood as a serum albumin complex. It is in the 
liver that copper is processed and stored as metaliothionin complex or 
converted into ceruloplasmin which is released into the blood to meet normal 
metabolic needs. 2o-22 
Tissue requirements for copper are believed to be met and controlled in a 
homeostatic fashion based on the absorption, storage, utilization and 
excretion.23 However, all tissues contain copper in the form of copper 
dependent components which include metallo-proteins, metallo-enzymes and 
low molecular weight (I.m.w) complexes of biological importance. 
Copper complexes were observed to be effective in the treatment of RA and 
other degenerative connective tissue diseasesY The traditional approach for 
RA treatment was by wearing copper bracelets. It was observed that through 
sweat, bracelets were solubilised and promoted dermal absorption of copper 
into the blood stream. However, the elevated serum copper levels during RA, 
and anti-arthritic properties of copper complexes led to the hypothesis that 
endogenous copper might have a protective function in chronic inflammatory 
conditions.22-25 The discovery brought about many articles in the literature 
indicating that copper complexes can be effective in the alleviation of 
inflammation aSSOCiated with RA. 
1.3.1 Possible modes of action of copper(II) complexes 
Important gains have been made concerning possible biochemical 
mechanisms of action of copper complexes in relieving inflammation. 
Although several possibilities exist, the mechanism of action by which copper 
exhibits anti-inflammatory activity is not yet fully understood. However, 
Sorenson discussed several modes whereby copper may exhibit its anti-
inflammatory activity.25 These include induction of Iysyl oxidase, modulation 
of prostaglandin synthesis, induction of superoxide dismutase or superoxide 
dismutase mimetic activity, stabilization of lysosomal membranes and 











1) Induction of Iysyl oxidase 
Lysyl oxidase is a copper dependent enzyme responsible for repair of 
damaged tissues due to inflammation. The process requires cross-linking and 
extracellular maturation of the connective tissue components, collagen and 
elastin. It has been observed that Iysyl oxidase activity is induced in copper 
deficient chicks by copper(II) sulphate administration. 26)7 
2) Modulation of prostaglandin synthesis 
Copper complexes have been shown to decrease the synthesis of the pro-
inflammatory prostaglandin, PGE2 and a concomitant increase in the synthesis 
of the anti-inflammatory prostaglandin, PGF2u ' 
3) Modulation of the activity of Histamine 
Modulation of the physiological effects of histamine may also be an important 
biochemical role for copper complexes. It is found that copper-histamine 
complexes are an active form of histamine. 
4) Stabilization of lysosomal membranes 
Copper is also found to be important for redox control of human synovial 
Iysosomes. The synovial fluid contains lysosomal enzymes which are 
destructive towards cartilage. The permeability of Iysosomes is found to be 
decreased by copper and in addition decreased the ratio of free versus bound 
lysosomal enzymes. 25 
5) Induction of superoxide dismutase and superoxide mimetic 
activity 
RA has been associated with deficiency or lack of superoxide dismutase 
enzyme activity. The human superoxide dismutase contains copper at the 
active site and is required for its dismutase activity. The superoxide anion 











1.4 DESIGNING Cu(II) COMPLEXES AS ANTI-INFLAMMATORY 
AGENTS 
The ab initio design of therapeutic agents usually depends on a knowledge of 
the difference between health and disease at a molecular level. 29 The 
evidence presented in the literature suggests that there is a localized 
deficiency of copper associated with RA. The fraction of copper concerned 
with localized deficiency is the labile component comprising the albumin and 
I.m.w. bound copper and the free metal ions. Most of the serum copper is 
non-reversibly bound to ceruloplasmin. The I.m.w fraction is involved in the 
transport of metal ions across cell membranes and between biological binding 
sites. However, their biological role is not easy to elucidate because they exist 
well below the limits of analytical means of detection. They are also not 
amenable to isolation and concentration techniques because these upset the 
labile equilibria in which they participate. 29 
A computer simulation of the equilibrium reactions between transition metal 
ions and I.m.w ligands was considered to be the only reliable way to 
determine which of the thousands of possible complexes would be important 
under biological or plasma conditions. A blood plasma model developed by 
May et a/ has been successfully used to account for several processes in drug 
therapy.3D This requires the thermodynamic formation constants for all 
complexes present in the mixture and the overall concentrations of the 
components. The model provided evidence in support of the hypothesis that 
administration of I.m.w copper complexes would be beneficial in the 
treatment of RA. 30-33 
The use of chelating drugs to displace the labile copper equilibrium away from 
plasma albumin in favour of the tissues is the most straight forward way of 
utilizing endogenous copper reserves. For this to happen, it requires a drug 
which is able to compete effectively with the protein for the metal ion and 











affected synovial tissue. The extent to which administered therapeuticals may 
be able to fulfil these conditions can be judged by simulating their effects in 
plasma using ECCLES (Evaluation of Constituent Concentrations in Large 
Equilibrium Systems) program. 34 In particular a function called plasma 
mobilization index (p.m.i) is used to ascertain whether the agent is sufficiently 
powerful and copper specific. 
The design of RA agents which reduce inflammation is based upon the 
assumptions that a). the therapeutic effect of copper administration arises 
from increase in the total labile copper concentration in the body 
compartments such as synovial fluid and b). the increase is due to the 
formation of complexes in plasma that can diffuse into synovial fluid through 
the separating membrane. The increase in the local concentration of copper 
at the site of inflammation may be achieved by the two general routes as 
illustrated in Figure 1.3.29,35 
The first route is based on the liberation of copper from endogenous reserves 
while the other on copper administration by oral or topical means. For short 
term therapy endogenous rather than exogenous sources seem appropriate. 
The endogenous route can be achieved by a) equilibrium competition for the 
labile protein-bound copper, b) decreasing the affinity of serum albumin for 
copper by allosteric effects and c) extracting copper from inert 
meta"oproteins. For oral or topical administration (exogenous route) it is 
essential to investigate copper chelating agents and their effects in improving 
the bioavailability of copper, and also explore their possible use in copper 
chemotherapy. The initial step would be to design and synthesise potential 
copper mobilizing agents (ligands) containing biofunctional groups or 
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Figure 1.3: Routes for increasing the concentration of I.m.w. copper complexes in 
blood plasma 
1.5 AIM AND OBJECTIVES OF THIS STUDY 
The aim of this study was to design ligands that would effectively mobilize 
copper(II) at the site of inflammation by increasing low molecular weight and 
membrane penetrable complexes in vivo. These ligands would also compete 











In order to achieve this aim, the following objectives were carried out; 
Design and synthesis of PrDH, PrOM, PrDPr and PCUA ligands. 
Determination of formation constants of these ligands with Cu(II), 
Zn(II), Ca(H) and Ni(II) in aqueous solution using glass electrode 
potentiometry. 
Elucidation of structures formed between Cu(II) and these ligands in 
solution using UV-visible, nuclear magnetic resonance and infrared 
spectroscopy as well as molecular mechanics calculations. 
Use of a computer blood plasma model, together with measured 
formation constants, to evaluate the plasma mobilizing ability of these 
ligands. 
Determination of octanol/water partition coefficients as an estimation 
for dermal absorption for Cu(H) complexes of these ligands. 
Determination of superoxide dismutase activity of Cu(II) complexes 
with these ligands using a simple in vitro assay. 
Finally, performing animal experiments for the determination of tissue 
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2. LIGAND DESIGN AND SYNTHESIS 
2.1 INTRODUCTION 
The rational approach towards ligand design for selective complexation of 
metal ions in solution for therapeutic purpose is of great importance. During 
inflammatory conditions there is an increase demand for copper and this is 
compensated for by enhanced intestinal absorption and decreased intestinal 
excretion of copper. However, the exogenous administration of copper(II) for 
this therapeutic activity requires ligands that can successfully mobilize metal 
ion at the site of inflammation. For this to happen, the ligands must possess 
desirable features. 
2.2 LIGAND SELECTION 
The design for the ligands that can successfully mobilize the metal ion in body 
fluids depends on the strength of complexes formed. Strong and kinetically 
labile complexes are mostly desirable. However, very strong or kinetically 
inert complexes might not release the metal ion at the biological active site. 
The design strategy in this study is to synthesise the ligands that would 
enhance absorption of copper(II) from the intestine or dermally, and thereby 
increasing the concentration of I.m.w complexes. The ligand could also be 
powerful enough to compete for or exploit copper bonded to serum albumin. 
There are several different ways of achieving selective thermodynamic 
binding in aqueous solution. 1,2 Amongst the criteria is Pearson's hard/soft-
acid/base (HSAB) theory in which CU2i is regarded as a borderline ion. 
According to tt-lis theory, a hard donor atom will prefer to bond to a hard 
accepter atom and likewise a soft pair of atoms. Moreover, if a range of 
complexes formed by one metal ion is known, the Irving-Williams series 
(Mg2+ <Mn2+ <Fe2+<Co2+ <Nj2+ <Cu2+>Zn2+) may be used to predict the 











been observed that the mobilizing efficiency on a ligand increases as the 
donor atoms change from 0 to S to N.7 Of interest is that copper(II) shows a 
remarkable ability to form bonds at pH ~ 7 to peptide and amide nitrogens in 
their ionized state. 
The increase in the stability of copper(II) complexes has been associated with 
increase in the number of donor atoms.8 In general, the stability of inorganic 
chelate complexes is affected by the size of the chelate rings formed upon 
coordination. For example, copper(II) complexes of 5,6,5 membered chelate 
system are generally more stable than 5,5,5 chelate analoques. 5 The low 
stability in the formation of the 5,5,5 membered chelate system is due to 
steric constraints. In the design of the copper(II) mobilizing ligands, nitrogen 
donor groups are preferred because of their high selectivity towards 
copper(II) over zinc(II) and calcium(II). The in vivo concentration of zinc(II) 
and calcium(II) are reported to be relatively high and thus can interfere with 
ligands designed to bind copper(II).8 
In summary, the following features would be desirable in designing the ligand 
that would successfully mobilize copper(II) in the body fluids at the biological 
active sites; 
strong complexation with copper(II) to form stable species under 
physiological conditions such as temperature and pH. 
high selectivity to copper(II) so that other metal ion equilibria such as 
calcium(II) and zinc(II) are not disturbed in their essential body 
functions. 
- formation of kinetically labile complexes to be able to transport and 
release copper(II) at the biological active sites. 
formation of neutral or rather formally uncharged complexes which are 
also lipophilic to enable transport across cell membranes. 
In this study related investigations performed by other authors have been 











copper mobilizing efficiency of a ligand increases as the donor atoms changes 
from 0 to S to N. Their investigations also show that as the number of donor 
atoms in the ligand increases, the stability of the copper complexes 
increased.8 However, no significant increase in mobilizing ability was observed 
above coordination number 4. The results led to the investigation of 3,6,9, 
tetra-azatetradecanedioic acid (TTDA) and 3,6,9-triazaundecanedioic acid 
(DTDA) (Figure 2.2). Neutrality of the copper complex was achieved by 
incorporation of two acetate groups on the ligand. These ligands formed more 
stable complexes with copper(II) than zinc(II) and calcium(II) but were found 
to be highly hydrophilic and rapidly excreted in urine.4,8,9 
Further investigations were carried out by Voye and co-workers for I'J,N'-bis 
[2(dimethylamino)ethyl]ethanediamide (SUM) and N,N'-bis [2(dimethylamino) 
ethyl]propanediamide (6UM) (Figure 2.2).36,41 This was done in order to 
increase the lipophilicity of the complex. The incorporation of the amide 
groups on the ligand was meant to bury the charge within the ligand. Upon 
metal coordination the amides are expected to lose their protons.49 It was 
observed that the copper complexes of these ligands were not neutral at 
physiological pH. The plasma model simulation studies showed that they were 
unable to effectively compete with endogenous ligands hence were poor at 
mobilizing copper in vivo.ll 
Gama-Mkhonta and co-workers investigated a series of penta-nitrogen donor 
ligands in order to improve both stability and lipophilicity of the 
complexes. ll ,12 They investigated l,13-bis (N,N-dimethyl)-S,9-dioxo-7-N-
benzyl-1,4,7,10,13-pentaazatridecane (BID), l,13-bis (N,N-dimethyl)-S,9-
dioxo-7-phenethyl-1,4,7,10,13-pentaazatridecane CDME), 1,4,7,10,13-
pentaaza-S,9-dioxo-7-N-phenethyltridecane (EDA) and l,13-bis (N,N-
dimethyl)-S,9-dioxo-l,4,7,10,13-pentaazatridecane (ZDA) (Figure 2.2). It was 
found from the results that these ligands indeed formed more stable 
complexes than their tetra-nitrogen analogues. Simulation studies showed 











must be noted that computer simulation does not take into account other 
factors such as hydrophilicity. Unfortunately biodistribution studies were not 
done for comparison with their analogues. 
Nomkoko and co-workers investigated dione dioximes ligands in which the 
secondary amines and dicarboxylates of TTDA were replaced. 13 3,3,9,9-
tetramethyl-4,8-diazatridecane-2,10-dione dioxime (PrAO) and N,N'-bis (2-
hydroxyiminopropionyl)propane-1,3-diamine (H 2PAP) (Figure 2.2) were 
synthesized and investigated. On the basis of simulation studies it was found 
that these could successfully mobilize copper in vivo without altering the 
equilibria of other endogenous metals. Biodistribution studies on mice gave 
relatively good results and hence prompting further evaluation and 
development of anti-arthritic agents. 15 The authors also investigated (1,15)-
bis (N,N-dimethyl)-5,ll-dioxo-8-(N-benzyl)-l,4,8,12,15-pentaazapentadecane 
(BIDPAP) and the results showed that the ligand is Ilot capable of mobilizing 
copper as compared to PrAO and H2PAP.
16 
The present study is an advancement of the investigation of polyamido 
ligands which possess some common properties as those of nitrogen-
containing biofunctional molecules such as oligopeptides. 17 They are 
tetra/penta-nitrogen donors and have diamide groups which upon metal 
coordination should lose their protons. 18 The dissociation of the amide 
protons would enable the formation of neutral species. The structures of 
these ligands are shown ill Figure 2.1. Incorporated ill these ligands are 
pyridyl groups. The benzyl and pyridyl groups are mainly found in most of the 
NSAIDs. However, Cu(II)-NSAIDs complexes are reported to be more 
effective than their parent NSAIDs. 19 The pyridyl group would be able to 
impose rigidity to the ligand system due to the aromatic ring system. The 
nitrogen on the pyridyl group should increase the stability of the complex by 
the chelate effect. It is expected that the nitrogen in the pyridyl group 
between amide groups on the ligand would act as all anchor for coordination. 











coordination. Moreover, the aromatic groups on these ligands should increase 
both complex stability and lipophilicity. 
PrDH 
I'rDP., 
o (NH HN) 0 
NH2 H2N 
PCTA 
Figure 2.1: Schematic representation of ligands in this study 
2.3 SYNTHESIS 
Solvents such as ethanol, chloroform, dichloromethane, acetone and 
triethylamine were purified using normal procedures20 and stored in bottles 
containing molecular sieve (beads) prior to use. These solvents as well as 
other reagents used were of analytical grade. All other reagents (starting 
materials) except those of purity 
purification. 
than 97% were used without further 










Table 2.1: Starting materials used for synthesis 
Chemical Purity Source 
i Dimethyl-2,6-pyridinedicarboxylate 99 % Aldrich 
Ethylenediamine 99 % i Aldrich 
2,6-pyridinedicarbonyl dichloride 97 % Aldrich 
I 
i N,N-dimethylenediamine 95 % Aldrich 
! 2(2-aminomethyl)-pyridine 95 % Aldrich 
ProtonCH) and carbon-13(13C) spectra were obtained from Mercury 300 IVIHz 
or Varian Unity Plus 400 MHz instruments. Chemical shifts were recorded in 
ppm with tetramethylsilane(TMS) (0 scale) as internal reference. Melting 
points(m.p.) were measured using Reichert Thermovar melting pOint 
apparatus while elemental microanalysis was carried out on a Fisons 
Elemental Analyser C H I\J 0 S. 
2.3.1 Preparation of N,N'-di{aminoethylene)-2,6-pyridine-
dicarbonylamine (PrDH) 
N,N'-di(aminoethylene)-2,6-pyridine-dicarbonylamine was synthesised 
according the method of Zeng and co-workers21 and Martell and co-workers.22 
Under nitrogen atmosphere dimethyl-2,6-pyridinedicarboxylate (4 g, 0.0204 
mol) dissolved in 50 cm3 methanol was added to a stirred methanol solution 
(120 cm 3) of ethylenediamine (9 g, 0.1498 mol). The reaction mixture was 
stirred at room temperature for 2.5 hours after which it was filtered. The 
solvent and excess ethylenediamine were entirely removed from the filtrate 
under reduced pressure using a rotary evaporator. Tile wh product 











was confirmed by NMR spectroscopy, melting point and elemental micro 
analysis (C H N). 
Yield 4.2 g (82%), slightly hygroscopic, m.p. 169 173°C (lit. 170 - 172 
0C)21, IH NMR( 400 MHz) i)H (CDCl3) 2.89 et, 4H, NCH2), 3.48 (t, 1H, 
C(O)NCH2), 7.91 (t, 1H, Py-Hp), 8.22 (d, 1H, Py-HM), 8.94 (br t, 2H, C(O)NH), 
13C NMR(100.6 IVIHz) 6c (CDCb) 41.41 (CH 2NH 2), 42.14 (NHCH2), 124.81 (Py-
C~.,), 138.92 (Py-Cp), 148.88 (Py-Co), 163.81 (C(O)NH), Elemental analysis 
Anal. found (calc. for CI1H17Ns02) C 51.71 (52.56), H 8.04 (6.83), N 27.05 
(27.87). The discrepancy between the observed and calculated values is 
probably due to the hygroscopic nature of the ligand 
2.3.2 Preparation of Bis-(N,N-dimethylethyl)-2,6-pyridine-
dicarboxamide (PrDM) 
Bis-(N,N-dimethylethyl)-2,6-pyridinedicarboxamide was synthesised according 
to the method of Danies and co-workers23 , and Mitchell and co-workers.24 
Under nitrogen atmosphere 2,6-pyridinedicarbonyl dichloride (4.82 g, 0.02755 
mol) in 35 cm3 dichloromethane was added dropwise to a stirred solution of 
I'J,N-dimethylenediamine (4.14 g, 0.04698 mol) and triethylamine (32.9 cm 3, 
0.236 mol) in 160 cm3 dichloromethane. The reaction was stirred for 1.5 
hours after which a slight precipitate formed. The dichloromethane was 
removed under reduced pressure to afford a red viscous liquid. This liquid 
was extracted into toluene (3x15 cm3), filtered and then all the volatiles were 
removed under reduced pressure. This resulting liquid was dissolved in 
dichloromethane and passed down through three columns of florisil (25 g 
each), each time eluting about 150 cm 3 of dichloromethane. The three 
aliquots were combined and the volatiles were removed under reduced 
pressure to afford a yellow solid. Recrystallisation from toluene gave white 
crystals. The structure of the compound was confirmed by NMR spectroscopy, 











Yield 2.2 g (26%), m.p. 118 - 120°C, IH NMR(400 tvlHz) OH (CDCI3) 2.31 (5, 
12H, NMe2), 2.58 (t, 4H, CH2NMe2), 3.62 edt, 4H, NCH2), 7.99 (t, lH, Py-Hp), 
8.31 (d, 2H, Py-Hr'1), 8.85 (br t, 2H, C(O)NH), 13C NMR(100.6 tvlHz) ()c (CDel3) 
36.93 (NHCH2), 45.26 (NMe2), 58.77 (CH2N), 124.71 (Py-CM), 138.65 (Py-Cp), 
149.03 (Py-Co), 163.92 (C(O)NH), Elemental analysis Anal. found (calc. for 
ClsH2SNs02) C 58.48 (58.61), H 8.24 (8.20), N 22.73 (22.78). 
2.3.3 Preparation of N,N'-bis[2(2-pyridyl)-methyl]pyridine 
-2,6 dicarboxamide (PrDPr) 
N,N'-bis[2(2-pyridyl)-methyl]pyridine-2,6-dicarboxamide was synthesised 
according to the method of Marlin and co-workers25, and Hirao and (Q-
workers. 26 Under nitrogen atmosphere 2,6-pyridinedicarbonyl dichloride (5 g, 
0.0245 mol) in 100 cm3 chloroform was added dropwise to a stirred solution 
of 2(2-aminomethyl)-pyridine (7.95 g, 0.0735 mol) in 150 cm3 chloroform at 
o 0c. The mixture was stirred for 1 hour and then heated to reflux at 60°C for 
2 hours. The solvent and excess 2(2-aminomethyl)-pyridine were removed 
under reduced pressure using a rotary evaporator. Recrystallisation from 
acetone gave a white solid and was dried under vacuum. The structure of the 
compound was confirmed by NMR spectroscopy, melting point and elemental 
micro analysis (C H N). 
Yield 5.1 g (60%), m.p. 150 - 154°C (lit. 151 - 153 oC)26 IH NMR(400 MHz) 
bH (CDel3) 4.81 (d, 4H, NCH2), 7.23 (m, 2H, Py-H), 7.39 (m, 2H, Py-H), 7.68 
(m, 2H, Py-H), 8.01 (t, 2H, Py-H), 8.34 Cd, 2H, Py-H), 8.47 (dd, 2H, Py-H), 
9.18 (t, 2H, C(O)NH), 13C NIVIR(100.6 MHz) ('k (CDCI3) 44.43 (NHCH2), 122.49, 
122.66, 124.78, 137.27, 138.73, 148.75 CPy-C), 148.71, 157.08 (Py-Ctert ), 
163.74 (C(O)NH), Elemental analysis Anal. found (calc. for C9Hl7Ns02) 












The synthesis of 3,5-bis[(aminoethyl)ethanediamide]-4-oxahexacyclo-
dodecane was performed by Professor H.G. Kruger and his group at the 
University of Kwazulu Natal (South Africa) who supplied us with this ligand. 
Elemental micro analysis and the results are presented as follows; Elemental 
analysis Anal. found (calc. for C19H28N402) C 63.76 (63.33), H 7.77 (7.76), N 
15.96 (15.55). 
The purity of these ligands were also confirmed by acid - base glass electrode 
potentiometric titrations at 25 DC and ionic strength, 0.15 moljdm3 and 
were found to be greater than 95 %. This was shown by an excellent fit 
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3. GLASS ELECTRODE POTENTIOMETRY 
3.1 INTRODUCTION 
Potentiometry is one of the oldest, most convenient and successful techniques 
employed for metal complex equilibrium measurements! and has expanded 
tremendously over the past decades. It has found a significant place in the 
study of many chemical systems in biological, medical and environmental 
studies.2 It is preferred because of its high sensitivity, non-invasiveness and 
easy accessibility. Glass electrode potentiometry (GEP) has been employed in 
this study because of the easy availability of the glass electrode, its linear 
Nernstian response, rapid reversibility and high sensitivity to aqueous 
hydrogen ions over a wide concentration range. However, the enhancement 
in the accuracy and predictability of the values arising from GEP require a full 
mastery of the principles behind electrode calibrations.2 
Of importance in this study is the determination of stability constants (also 
known as formation constants) using GEP. The stability constants provide a 
quantitative measure of the extent to which a metal ion will complex a 
particular group or Iigand.3 A large number of stability constants have been 
reported in the literature.4 Since different workers may report a range of 
stability constant values under a particular set of conditions, a set of stability 
constants may be comparable if they have been measured under similar 
experimental conditions. It is important to note that the position of 
equilibrium and hence the numerical value of the reported stability constants 
when expressed in concentration units, is normally dependent upon the 













Theory on formation constants and methods used to determine these 
constants have been widely covered in the Iiterature.1,2,6-9 
Considering a general metal-ligand formation equilibria involving metal ion 
(M) and ligand (L), the thermodynamic equilibrium constant is defined as 
follows; 
M+L ML TK = {ML} 
1 {M}{L} 
(3.1) 
where the symbol { } denotes activity. This equation can be rewritten in 
terms of concentration; 
{ML} = YML[ML] (3.2) 
where Y ML is the activity coefficient of the ML species. 
(3.3) 
The expression --'-'-=- becomes a constant at constant ionic strength (1) and 
YM Yt 
therefore, cK, is a constant (3.4) 
Hence, the stepwise formation of the parent complexes can be described by 
the following set of formation constants at constant ionic strength; 
M+L ML K = [ML] 
1 [M][L] 














MLn_1 + HL MLn + H 
K = [MLn][H] 
n [MLn.1][H L] 
(3.7) 
The charges on the species have been omitted for clarity. The product of 
individual formation constants gives characteristic constants called overall 




- K - [ML] 
~l - 1 - [M][L] 
fl = K K = [ML2 ] 





Moreover, the stability constants are affected by temperature as represented 
by the Van't Hoff equation; 
dink L'iHo 
dT = RT2 
(3.12) 
where ~Ho is the standard enthalpy change of reaction and is related to Gibbs 
free energy ~Go and entropy ~so changes of reaction, T is absolute 
temperature in Kelvin and R is the universal gas constant in ] K-1mor1• 
For a complex formation reaction occurring between a metal ion M, ligand L 













where P, q and r are the stoichiometries of the components in the complex. 
The formation constant for this reaction is described by the mass balance 
equation as follows; 
(3.14) 
and the concentration of each species MplqHr in the kth point is given by; 
(3.15) 
The total concentration of the metal ion (T M), ligand (Td and hydrogen ion 
(T H) described by law of mass action at kth point will be; 
N 
Tk,M = [M]k + L p ~pqr [M]k[L]~[H]~ (3.16) 
i=l 
N 
Tk,L = [L]k + I q ~pqr [M]k[L]~[H]~ (3.17) 
i=l 
N 
Tk,H = [H]k + I r ~pqr [M]aL]~[H]~ (3.18) 
i=l 
where [M]k is the concentration of free aquated metal ions and the 
summation is over the concentration of all the metal containing species which 
may be protonated (r>O) or may not (r=O), [L]k is the concentration of the 
uncomplexed ligand and the summation is over the concentration of all the 
protonated and unprotonated ligand containing species and [H]k is the 
concentration of hydrogen ion. 
It is possible that r may be less that zero (r<O) in which case either a proton 
has been lost from the complex or a hydroxide ion has been added. In this 











1 1 -1 denotes the complex species MLH-1 with r=-l referring to the removal 
of a proton from either a coordinated ligand or a bound water molecule, or 
hydroxide ion addition to the complex.12f13 MplqHr can be regarded as a 
protonated complex if 1. 
The electrode cell is the centre of any potentiometric investigation. An 
electrochemical cell consisting of a test solution surrounding a glass electrode 
in electrical contact with a reference electrode through a salt bridge can be 
represented as follows; 
Hal~ cell Hal~cell 
t \ 
glass electrode test solution reference electrode 
g 
From the reaction cell, the observed potential (Ecell) is due to the potential 
difference between the glass electrode and the reference electrode (Eref), the 
potential of the liquid junction of the reference electrode (EIj) and the 
potential at the membrane of the glass electrode (Eg). The reaction cell 
potential may be represented by the following equation; 
Ecell = Eref + EIj + Eg (3.19) 
The glass electrode (half cell) generates a potential that is proportional to the 
logarithm of the analyte activity (concentration) and is measured relative to 
an inert reference electrode that is in contact with the sample solution.14 The 
Nernstian equation is therefore stated as follows; 













where Ecell is measured electromotive force (emf), EgO is the standard 
electrode potential, R is the gas constant, T is the temperature of the system, 
F is Faraday constant and {H+} is the activity coefficient of the hydrogen ion. 
The activity (a) of the hydrogen ion (i) is defined with respect to its activity 
coefficient (y) and concentration (c) as follows; 
(3.21) 
The ionic strength (1) of a solution is defined by the expression; 
(3.22) 
where Cj is the concentration of ionic species i and Zj is the charge on that ion. 
The activity coefficient of hydrogen ions becomes a constant at constant ionic 
strength. Since the concentration of the hydrogen ions is a measurable 
quantity, the cell potential becomes; 
Ecell = Econst + RT In[H+] 
F 
(3.23) 
The temperature dependence of the potential response for hydrogen ion 
activity (concentration) is demonstrated by the slope factor, s = 2.3~3RT , in 
the Nernst equation; 
Ecell = Econst + S log[H+] (3.24) 
3.3 EQUILIBRIUM SIMULATION FOR TITRATION ANALYSIS 
The Equilibrium Simulation for Titration Analysis (ESTA)15 is a flexible, 











formation constants in aqueous chemical equilibria. This program library is 
used to calculate equilibrium distributions of chemical species, to analyse 
potentiometric titration data and to manipulate titration data for a variety of 
purposes. The calculations are performed using a Gauss-Newton method to 
solve the mass balance equations. 
The Gauss-Newton method is used to minimize the objective function, UObj, in 
the ESTA program. The objective function is optimized by the task OBJE 
within the ESTA2 module. The optimization is done with respect to the 
observed emf. In contrast, with the OBJT task, optimization is based on total 
concentrations. Since the variation in total concentrations is smaller than the 
variation in emf, OBJT is more robust and faster than OBJE but is less 
sensitive. Thus in practice OBJT would often be used for initial optimization 
followed by OBJE for the final optimization. The ESTA program also calculates 
two important functions which are the formation function, Z-bar, and the 
deprotonation function, Q-bar. These functions are calculated by the tasks 
ZBAR and QBAR within ESTAl module. They are defined differently for the 
ligand, the binary and the ternary systems. This is because the kinds of 
equilibria present in the different systems may vary depending on the number 
of the components that constitute each system. 
The program ESTA also incorporates the task SPEC in the ESTAl module and 
this calculates the distribution of species present in an equilibrium system as 
a function of the pH of the solution. 
3.3.1 The Objective function 
The objective function (UObj)16 may be described as the summation of all the 
squared residuals of the real parameter values from the calculated values. 












Uobj = (N - npr1Ine-1IWnq (ynq°bs_ ynqcalc)2 (3.25) 
n=l q=l 
where N is the total number of experimental pOints, np is the number of 
parameters being optimized, ne is the total number of electrodes, wnq is the 
weight of the qth residual at the nth pOint, ynqObS is the observed variable of the 
qth residual at the nth point and ynqcalC is the calculated variable of the qth 
residual at the nth point. 
The optimization of the resulting data can be achieved by minimization of the 
objective function. In order to minimize Uobj, a Gauss-Newton approach is 
employed and this assumes that the function is quadratic with respect to all 
the parameters. Therefore Uobj can be expressed as; 
(3.26) 
where a and b are Gauss-Newton quadratic parameter vectors, p is the 
optimization parameter vector, pt is the transpose of p and H, the Hessian, is 
given by; 
(3.27) 
A well defined system with good initial estimates often converges. The 
calculations are terminated if the resultant shift vectors are large or if the shift 
vector has an upward gradient. Once the UObj is minimized, the standard 
deviation, the Hamilton R-factor and its limit and the correlation coefficients 












3.3.2 Formation and Deprotonation functions 
The ESTA programs calculate two important functions from the titration data. 
These functions are the formation function (Z-bar) and the deprotonation 
function (Q-bar). These functions are defined differently depending on the 
presence or absence of a metal ion. 
In the absence of a metal ion the protonation function is expressed as; 
(3.28) 
where TL is the total ligand concentration and TH* is the total hydrogen ion 
concentration and is defined by; 
(3.29) 
The ZH-bar function is plotted against pH. ZH-bar may be described as the 
average number of hydrogen ions bound to the ligand at each pH. 
The complex formation function, ZM-bar, measures the average number of 
ligands bound per metal ion at each concentration of the ligand. This function 
may be represented as; 
ZM-bar = TL - [L] 
TM 
(3.30) 
where TM is the total metal concentration and [L] is the free-ligand 
concentration. ZM-bar applies only to mononuclear binary complexes. A plot of 












On the other hand, the deprotonation function, QM-bar, is the average number 
of protons released from the ligand per metal ion as a result of complexation. 
(3.31) 
where TH is the total proton concentration and TH* is the calculated total 
concentration of protons that would be necessary to give rise to the observed 
pH in the absence of the metal ions or rather if no complexation took place. 
In binary systems, a formation function representing the number of protons 
that would be on the ligand in the absence of the metal ion, is simultaneously 
defined as; 
(3.32) 
The difference between n-bar and QM-bar gives the number of protons on the 
complex. This can be represented as; 
r = ( q x nbar ) - ( Qbar X P ) (3.33) 
where p and q are the stoichiometric coefficients of the metal and the ligand 
respectively. If p = q = 1, and nbar = Qbafl then r = 0 and hence the ML 
species stability constant is given by ~110' For r < 0, it is either the 
deprotonation of the complex formed or the formation of the hydroxo species. 
Polynuclear complexes arise whenever there is a ligand capable of bonding to 
more than one metal ion. Such ligands include hydroxide, carboxylate etc., as 











3.3.3 Standard deviation and Hamilton R-factor 
Standard deviationsl6,17 are errors estimated for the parameters being 
optimized by the method of least-squares. The standard deviation of the rth 
optimized parameter may be calculated as follows; 
Or = [UObj X Grr ]005 
N - np 
where G is the reciprocal of the Hessian, G = H-1 
(3.34) 
The agreement between the experimental and calculated values of the 
refined data is indicated by the Hamilton R-factor.16 It is represented as: 
(3.35) 
The R-factor is compared with its limit as follows: 
(3.36) 
where symbols have their usual meaning as outlined in section 3.3.1. The 
Rlim H is the best possible R value based on the random error in the analytical 
data and the number of variables. Thus the closer RH gets to the Rlim H the 
better the agreement between the theoretical model and the experimental 
data. However, if RH < RlimH the model is within the maximum allowed 













Potentiometric titrations were performed using a Metrohm 6.0222.100 
Combined LL pH glass electrode. The slope of the electrode system was 
calibrated in terms of hydrogen ion activity using buffer solutions of known 
pH and Econst determined by strong acid - strong base titrations at 25°C. The 
emf was monitored using a Radiometer PHM 84 Research pH meter. The 
reaction vessel was kept at a constant temperature of 25°C by circulating 
water from a thermostated water bath. Titrant such as sodium hydroxide 
(NaOH) was dispensed by the use of Metrohm 665 Dosimat piston burette. 
All titrations were performed under an inert atmosphere of nitrogen. This 
nitrogen was purified by passing it through a series of gas bottles containing 
50% potaSSium hydroxide to remove carbon dioxide (C02)' Fieser's solution to 
remove traces of oxygen (02), glass wool, distilled water and background 
electrolyte solution of ionic strength 0.15 mol/dm3 (Cr)Na+ to humidify the 
gas. The potentiometric titration system was controlled and monitored 
through a computer. 
3.4.2 Preparation and standardisation of solutions. 
All solutions were prepared with recrystallized NaCi as background electrolyte, 
at ionic strength of 0.15 mol/dm3 (Cr)l\Ja+ using glass distilled water which 
had been boiled to remove CO2 and kept in a container protected by a C02 
trap. All reagents except ligand samples were commercially available and of 
analytical grade. These were used without further purification. 
Hydrochloric acid (HCI) solutions were prepared to a concentration of 0.02 M 
from Merck ampoules (1.09973 - Titrisol) in background electrolyte. The 











decahydrate (borax) Na2B40 7 ·10H20. NaOH solutions were prepared under a 
nitrogen atmosphere to a concentration of 0.1 M from Merck ampoules 
(1.09959 - Titrisol). Standardisation of these solutions was done against 
recrystallized potassium hydrogen phthalate (KHP) using the Gran method.2o 
The 0.1 M NaOH solutions were further standardised against 0.02 M HCI 
solutions. The acid - base titrations were also used to check the carbonate 
content of the NaOH solution by use of the Gran method.20 
Solutions of ligands were prepared by dissolving accurately weighed samples 
and standardized by acid - base titrations according to the Gran 
method.20,22,23 The dissolution of PrDPr samples was enhanced by preparing 
samples in O.OlM HCI, stirring overnight and then heating. Standard solutions 
of divalent cations Cu(II), Ni(II), Ca(H) and Zn(H) were prepared from CuCb . 
2H20, NiCb . 6H20, CaCb' 2H20 and ZnCb respectively. These solutions were 
standardised by direct titration against 0.01 M standard solution of the 
disodium salt of ethylenediamine tetra acetic acid (EDTA) using standard 
methods.19,21 The concentrations of the metal ions ranged between 0.01898 
mol/dm3 and 0.02013 mol/dm3. A small amount of standardised HCI was 
added to the metal ion solutions to prevent hydrolysis of the metal ions.24 The 
formation of the metal hydroxide would give inaccurate concentrations of 
hydrogen ions present in the metal ion solution. 
3.4.3 Titrations and Data analysis 
Prior to acid - base titrations the electrode was calibrated and the Nernstian 
slope was determined using buffer solutions of pH values 4.00, 6.85 and 9.18 
prepared according to Vogel's method.19,21 The calibration of the glass 
electrode was performed to suit the conditions such as temperature (25°C) 
and ionic strength (I= 0.15 mol/dm3). The strong aCid-strong base titrations 
were performed in order to calculate the values of the response intercept 
(Econst), slope (s) and the dissociation constant of water (pKw) by introducing 











and 59.03 over the pH range of 2 to 11. The values of Econst varied between 
348.41 mV and 353.20 mV while the average pKw value was 13.73. 
The ligand protonation titrations were performed by dispensing aliquots of the 
ligand solutions into the titration vessel. The standardised HCI solution was 
dispensed into the vessel to ensure complete protonation of the ligand and 
diluted to 20 cm3 using background electrolyte solution. This solution was 
titrated against the standardised NaOH solution at 25 dc. The same procedure 
was carried out for the metal-ligand complexometric titration but with initial 
varying concentrations of the metal ions. The concentration of the metal ions 
in the resultant solution varied between 3.13 x 10-4 mol/dm3 and 1.02 x 10-3 
moljdm3• The initial varying concentration ratios of ligand to metal (Cl / CM) 
varied from 1.01 to 3.33. 
The data obtained from these titrations were input into ESTA file templates 
for the determination of protonation and stability constants. The task BETA of 
the ESTA programs was used to evaluate the initially estimated complex 
species and their formation constants. The output of this task was introduced 
into the task OBJE within the ESTA2A module to give optimised values of the 
stability constants and the ligand concentration describing the system. 
Complex formation and deprotonation functions were calculated from stability 
constants obtained using the tasks ZBAR and QBAR within the ESTA1 module 
to find out if the model fitted the system. The models were assumeed to be 
plausible when the observed and calculated plots of the ZH-bar, Zwbar and 
Qwbar overlapped and output data gave acceptable values of standard 
deviation and Hamiltonian R-factors. Finally the task SPEC within the ESTA1 
module was used to calculate the species distribution as a function of pH for 











3.5 RESULTS AND DISCUSSION 
3.5.1 Protonation formation function 
The protonation constants for H+ - L equilibria were evaluated in the pH range 
2 - 11 and were determined using the ESTA library of computer speciation 
programs. The protonation curves and species distribution graphs for the 
ligand systems obtained from the output data are presented in Figures 3.1 -
3.3. The protonation constants for the ligands PrDH, PrDM and PrDPr are 
given in Table 3.1. The protonation constants for PCUA are included for 
comparison. 
3.5.1.1 H+ -[PrDH] system 
Figure 3.1(a) shows the protonation formation function, ZH-bar, as a function 
of pH for the ligand PrDH. The function levels off at 2 and then rises slightly 
above 2.2 indicating that there are three dissociable protons in the ligand 
system. The levelling at ZH-bar = 2 is due to protons added to the terminal 
primary amino groups in the ligand. The rising of the function at low pH (pH 
< 2.4) is due to the protonation of the acidic pyridyl nitrogen. However, the 
function curve did not rise to ZH-bar = 3 because complete protonation of the 
pyridyl nitrogen occur below the reliable measurable pH range of our glass 
electrode is 2 - 11. 
An excellent agreement between the theoretical and experimental curves for 
different total ligand concentrations in Figure 3.1(a) lends confidence to the 
model. This is also supported by low standard deviations in log~oqr and 
Hamilton R-factors. Figure 3.2(b) shows calculated species distribution curves 
for PrDH. The plots indicate that the ligand solution has a mixture of di-
protonated and tri-protonated species at pH < 4. The di-protonated species 
predominates at pH < 8.3 whereas the neutral form of the ligand 

































2.3 4.3 6.3 8.3 10.3 
pH 
(b) 
Figure 3.1 (a): Protonation formation curves for PrDH versus pH. The symbols 
represent titrations performed with different starting ligand concentrations, [ (0) 
0.0012 and (D) 0.0031 mol dm-3 ] and theoretical (solid line) curve. (b): calculated 
protonation species distribution curves against pH for ligand PrDH. 
3.5.1.2 H+ -[PrOM] system 
Figure 3.2(a) shows average number of protons bound to ligand PrOM as a 
function of pH. As in the PrOH system, the protonation function curve 
indicates that there are three dissociable protons in the PrOM system. The 
levelling off at Zwbar = 2 reflects two similar protons added to the terminal 
amino groups and the rising of the curve at pH < 2.4 is indicative of a proton 
adding to the pyridyl nitrogen group. At 11igh pH (pH > 9.8) the curve levels 
off at zero indicating that the last proton is lost at this pH. 
The theoretical and experimental curves are well superimposible, and this, as 
well as the low standard deviations and Hamilton R-factors confirm the 
validity of this model. The calculated and species distribution curves shown in 
Figure 3.2(b) indicate that the solution has a mixture of di-protonated and tri-
protonated species at pH < 3.5. The di-protonated species predominates at 
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(b) 
Figure 3.2 (a): Protonation formation curves for PrDM as a function of pH for 
different starting ligand concentrations, [ (<» 0.0013 and (0) 0.0034 mol dm-3 ] and 
theoretical (solid line) curve. (b): calculated protonation species distribution curves 
as a function of pH for ligand PrDM. 
3.5.1.3 H+ -[PrDPr] system 
The Zwbar function in Figure 3.3(a) indicates that there are three dissociable 
protons in the PrDPr system. Unlike the previous systems, the PrDPr curves 
do not level off at ZH-bar of 2 although there is an inflection at this point. The 
reason for this is the overlap of the three protonation steps. This is clearly 
seen in the speciation diagrams (Figure 3.3(b)). At pH = 6.2 (ZH-bar = 0) the 
ligand is shown to be unprotonated. 
The excellent agreement between the experimental and theoretical curves as 
well as the low standard deviations and Hamilton R-factors lends confidence 
to this model. The calculated speciation graphs in Figure 3.3(b) show that the 
solution has a mixture of protonated species at pH range 2.2 - 6.2. This is 
because of the closeness of pKa values for the protonated sites of the ligand. 
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(b) 
Figure 3.3 (a): Protonation formation curve as a function of pH for different 
starting ligand concentrations, [ (0) 0.0010 and (D) 0.0031 mol dm-3 ] and 
theoretical (solid line) curve. (b): calculated protonation species distribution curves 
as a function of pH for ligand PrDPr. 
3.5.1.4 Discussion - Protonation 
The protonation constants for the H+ - L equilibria are presented in Table 3.1. 
Protonation or deprotonation of the amide nitrogens was not observed 
because they are too basic (pKa 2: 15)28 for the measurable pH range 2 - 11 
of our glass electrode. Several workers28-31 have also observed that 
protonation of the amide nitrogen is not possible in this pH range. However, 
reports show that the deprotonation of the amide protons is facilitated by the 
presence of metal ions such as copper(II).27,28 The results show low standard 
deviation and R-factors for all protonation models and the R-factors are close 
or less than their corresponding limits thus giving confidence in the chosen 
models. 
PrDH has three measurable acid dissociation constants with PKal = 2.032 for 
the pyridyl nitrogen, PKa2 = 8.684 and PKa3 = 9.197 for the two terminal 
amines. The low pKa or rather acidity of the pyridyl nitrogen is due to the 











group.32 The pKa values of the pyridyl nitrogen in pyridine and 2-
methylpyridine are reported as 5.34 and 6.14 respectively.33 The introduction 
of a carbonyl group in 2-methylpyridine to afford 2-acetylpyridine gives a 
pKapy value of 2.66.
4 Therefore, it would be expected that the pyridyl 
protonation constant in PrDH to decrease further when two amide groups are 
present. The difference in pKa's of the two terminal amines by 0.513 log units 
indicates repulsion when a proton is added to a molecule already containing a 
proton. The pKa values of this ligand agree with those determined by 
Motekaitis and Martell.25 The variation is due to the fact that experiments 
were performed in different solvents. Motekaitis and Martell carried out 
titrations using 70% dioxane - 30% water solution. 
Table 3.1: log~pqr\s of PrOH, PrOM, PrOPr and PCUA determined at 25°C and 
I = 0.15 mol dm-3 (Cr)Na+. Opqr denotes the standard deviation in log~01rl RH is the 
Hamilton R-factor and R1im H its limit, nT and np are the number of titrations and 
pOints respectively. The general formula of a complex is Mpl.qHr denoted by the 




















































/ RH I RlimH i n,{np) . Lit. 
0.009 0.010 2(162) 9.4225 
17.95 
19.77 
0.010 0.012 2(144) 
0.011 4.6 24 0.010 0.012 2(154) 
0.012 3.5 08 
0.047 1.9 79 
0014 19.517 
0.016 8.292 
0.013 0.019 2(168) /9.5226 
i 17.81 
A similar protonation scheme is observed for PrDM with PKal = 1.738, PKa2 = 
8.071 and PKa3 = 8.647 for the pyridyl nitrogen and two terminal tertiary 
amino groups respectively. The observable reduction in pKa's for the terminal 











from primary to tertiary amines. The difference of 0.576 log units between 
PKa2 and PKa3 is almost equal to that of PrDH. The decrease in basicity for the 
terminal amino groups is observed in related ligands, N,N'-bis[aminoethyl] 
ethanediamne, i.e. H2N-CHr CHrNH-C(O)-C(O)-NH-CH2-CHrl\lH2J 5UH, 
(logKHl = 9.31 and logKH2 = 8.43)34,35 and N,N'-bis[2-(dimethylamino)-ethyl] 
ethanediamide, i.e. Me2N-CHrCHrNH-C(O)-C(O)-NH-CHr CHrNMe2f SUM, 
(logKHl = 8.72 and logKH2 = 7.92).29,36 PCUA exhibits more basic terminal 
primary amines due to the positive inductive effect of the large number of 
carbon atoms in the cage mOiety.26 
PrDPr shows three pKa values arising from three pyridyl nitrogens. The PKal = 
1.979 is assigned to the protonation of the central pyridyl nitrogen whereas 
PKa2 = 3.508 and PKa3 = 4.624 are for the protonation of the terminal pyridyl 
nitrogens. The chemical environment associated with the central pyridyl 
nitrogen is the same as that found in PrDH and PrDM thus giving the same or 
very close PKal values. However, PKa2 and PKa3 values are greater than the 
PKal value because terminal pyridyl groups have methyl groups adjacent to 
pyridyl nitrogens. Unlike the CONH group which lowers the basicity of the 
pyridyl nitrogen, the methyl group increases the basicity by a positive 
inductive effect. The difference of 1.116 log units between pKa2 and pKa3 
indicates electronic repulsion on addition of a proton to a charged species or 
rather to an already doubly protonated molecule. 
3.5.2 Complex formation and deprotonation functions 
The stability constants (log~pqr) were evaluated and confirmed by the ZM-bar 
and Qwbar functions derived from experimental data. The complex formation 
function, Zwbar, measures the average number of ligands bound per metal 
ion due to complexation. This function is plotted against the negative 
logarithm of the free ligand concentration (pL). The deprotonation function, 
Qwbar, which indicates the average number of protons released due to 











which measures the average number of protons that would be bound to the 
ligand in the absence of complexation. 
3.5.2.1 M2+ -[PrOH] systems 
Figure 3.4 shows the complex formation curves as a function of pL and, 
deprotonation function curves and species distribution graphs against pH for 
the ligand PrDH with eueII). The ZM-bar function in Figure 3.4(a) levels off at 
1.5 indicating that ML is not the predominant species in solution. In fact 
MLH-l is the predominant species as shown by speciation graphs in Figure 
3.4(c). At pH 8.1 this species reaches 98% formation whereas rvlL reaches 
36% formation at pH 6.3. Moreover, the fanning back for higher metal to 
ligand ratios indicates loss of an amide proton upon metal coordination.37,38 
The deprotonation function in Figure 3.4(b) rises to maximum value of about 
2.7 at pH 7.8 indicating that approximately three protons have been released 
from the ligand due to complexation. At this pH the ligand has only two 
protons or rather QM-bar(=2.7) > n-bar(=2) suggesting the formation of 
MLH-l species as a result of the release of an amide proton. The falling of QM-
bar curves parallel to the n-bar curve indicates no further complexation. 
However, at pH > 9.5 these curves rise due to the presence of hydroxo 
and/or mixed hydroxo species or rather formation of the MLH-2 species. From 
the speciation graphs MLH-l predominates over a wide pH range of 6.4 - 10 
and, MLH and ML species do not exceed 30% formation. It is also observed 
that complexation commences at about pH 4 when the protonated rvlLH 
species is formed. 
An excellent agreement between the theoretical and experimental complex 
formation and deprotonation functions at different metal to ligand ratios 
supports the potentiometric model chosen in data analysis. Titrations were 
replicated under identical conditions and this showed good reproducibility. 











optimization process. The low standard deviation and Hamilton R-factors also 
lend confidence to the selected model. It is worth noting that several possible 
species were tried but were rejected by the optimization process. 
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Figure 3.4 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1: 1(0), 1:2(0) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with IVI(O.OOOSl 











Table 3.2: logppqr'S of PrDH with Cu(II), Ni(II), Zn(II) and CaCH) determined at 
25°C and I = 0.15 mol dm-3 CCr)Na+. Other symbols have their usual meaning as 
defined in Table 3.1. 
.. 
! pq r ! ny{np) Ligand Metal Log(3pqr Opqr RH RlimH 
ion 
PrDH Cu(II) 1 1 1 14.810 0.058 0.021 0.012 6(481) 
1 1 0 8.686 0.043 
1 1 -1 2.518 0.021 
1 1-2 -7.639 0.028 
2 1-3 -7.322 0.142 
Ni(II) Modell 
111 13.878 0.012 0.021 0.011 6(496) 
1 1-1 -1.818 0.016 
1 1-2 -10.919 0.019 
Model 2 
110 6.079 0.036 0.041 0.022 
1 1-1 -2.004 0.036 
1 1-2 -10.938 0.037 
Zn(II) 1 1 1 13.157 0.041 0.020 0.011 6(472) 
1 1 0 4.293 0.131 
1 1 -1 -3.418 0.027 
1 1 -2 -13.612 0.241 
Ca(II) 1 1 1 12.321 • 0.036 0.014 0.011 6(428) 
1 1 0 3.007 0.038 
I 
1 1 -1 -8.866 0.232 
For the complexation of PrDH with Ni(II), the ZM-bar function shown in figure 
3.5(a) rises steadily to a value of approximately 0.5 before steeply rising to 
ZM-bar > 1.5. This indicates the presence of MLH species39 and it is clearly 
shown by the species distribution graphs in Figure 3.5(c) where this species 
reaches up to 48% formation at pH 7.2. The fanning back of the ZM-bar 
curves indicates the presence of hydroxo species. 
On the other hand the QM-bar curves in Figure 3.5(b) rise to the value 2.7 at 
pH 8.3 thus indicating the release of approximately three protons due 
complexation of PrDH with Ni(II). At this pH, Qw bar(=2.7) > n-bar(=2) 
indicating the formation of MLH-l species which reaches up to 62% formation 











parallel to the n-bar curve indicating no further complexation before rising at 
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Figure 3.5 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1: 1(0), 1:2(0) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (c): calculated species distribution graphs [with M(O.OOOSO 
mol dm·3) - L(O.00104 mol dm·3)] as a function of pH for ligand PrDH with Ni(II). 
The potentiometric data analysis by the ESTA suite of programs gave two 
models for the Ni(II)-PrDH system. These models are presented in Table 2 
and consist of MLH'2, MLH'l and either ML or MLH. This posed a difficulty in 
deciding on the model which best describes the system because they both 
generated the same theoretical and experimental formation and 
deprotonation functions with excellent agreement and reproducible replicates 











and Hamilton R-factors also lend confidence to these two models. The two 
models describe the experimental data equally well as far as statistical criteria 
are concerned and also on chemical grounds. However, the model with the 
MLH species is most likely to be formed based on the splitting of the Qwbar 
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Figure 3.6 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1:1(0), 1:2(¢) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.00047 
mol dm-3) - L(O.00104 mol dm-3)] as a function of pH for ligand PrDH with Zn(II). 
Like l'Ji(II)-PrDH system, the Zwbar function for the Zn(II)-PrDH system 
shown in Figure 3.6(a) does not level at 1 indicating that ML is not the 
predominant species. The metal assisted amide deprotonated MLH-l species is 











of ZM-bar is characteristic of the presence of hydroxo and/or mixed hydroxo 
species. ML species coexist with significant levels of MLH and MLH-l over the 
pH range 7.5 - 9.5. 
The deprotonation function curves in Figure 3.6(b) show that complexation 
commences at pH 5.5. The rising of QM-bar at pH > 9.5 is indicative of the 
presence of hydroxo species. The potentiometric data analysis gave results 
for the model presented in Table 2 with low standard deviation and Hamilton 
R-factors. The model is also confirmed by the excellent agreement between 
the theoretical and experimental formation and deprotonation function curves 
for different metal to ligand ratios. 
Unlike the metal ions discussed above, Ca(II) seems to have low but 
measurable affinity for the donor atoms of ligand PrDH. This is confirmed by 
the complex formation function in Figure 3.7(a) which does increase to 
significant levels in the pH range investigated. 
Furthermore, the Qwbar function remains almost constant at a value close to 
zero as shown in Figure 3.7(b). The splitting of the QM-bar and ZM-bar 
function curves at pH < 9 is due to the presence of the MLH species. 
Moreover, this species dominates at a wide pH range 6.5 - 10.5 as illustrated 
by the speciation graphs in Figure 3.7( c). Despite this limited complexation, 
there is, however, a good agreement between the theoretical and 
experimental Zwbar and Qwbar functions to validate the selected model. The 
low standard deviation and Hamilton R-factors given in Table 2 also lend 
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Figure 3.7 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1:1(0), 1:2(0) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.00047 
mol dm-J ) - L(O.OO104 mol dm-J)] as a function of pH for ligand PrDH with Ca(II). 
3.5.2.2 M2+ -[PrOM] systems 
The complex formation behaviour of the Cu(II)-PrDIVl system is shown in 
Figure 3.8(a). The Zwbar shows that ML is not the predominant species by 
levelling off at approximately 1.5. The speciation graphs in Figure 3.8(c) show 
that ML, MLH-l and MLH-2 are present in significant levels i.e. 68% (pH 6.5), 
84% (pH 8.1) and 100% (pH 10.8) formation respectively. The fanning back 
of the curves at high pH for high metal to ligand ratios is presumably due to 











The rising of Qwbar to 2.6 in Figure 3.8(b) indicates that metal assisted 
deprotonated MLH-l is being formed. The function also rises at pH > 9 due to 
the presence or dominance of the MLH-2 species. The optimization process by 
the ESTA programs gave three models for the Cu(II)-PrDM system presented 
in Table 3.3. For model 2 and 3 the species calculated are ML, MLH-l' MLH-2 
and either M2LH-2 or M2LH-3 whereas model 1 consists of MLH, ML, MLH-l and 
MLH-2 species. These posed difficulties in deciding on the model which best 
describes the system. The three models gave the same theoretical and 
experimental Zwbar and QM-bar functions. However, the calculated speciation 
graphs for model 1 and 2 showed insignificant levels of formation for MLH 
and M2LH-2 species respectively. In fact both species are present at formation 
levels of less than 1%. For model 3, M2LH-3 species reaches up to 2.8% 
formation as shown in Figure 3.8( c). Possibilities exist in forming these 
relatively insignificant species as will be presented under discussion -
complexation section. The model 3 has been chosen to represent the 
Cu(II)-PrDM system based on the statistical data given in Table 3.3 and also 
function curves and speciation graphs. The results for all these models show 
low standard deviations and Hamilton R-factors as well as excellent 
agreement and reproducibility of repeat titrations at different metal to ligand 
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Figure 3.8 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1: 1(0), 1:2( ¢) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.OOOSl 
mol dm-3) - L(O.00109 mol dm-3)] as a function of pH for ligand PrOM with Cu(II). 
For the Ni(II)-PrDM system, the metal ion appears to coordinate weakly to 
PrDM. This is revealed by the Zwbar in Figure 3.9(a) which remains close to 
zero before fanning back at pL :::; 4. This is indicative of the formation of 
hydroxo and/or mixed hydroxo species. The MLH is the minority species (~ 
15% formation) in solution as shown in Figure 3.9(c). The QM-bar in Figure 
3.9(b) rises at pH > 9.5 due to the formation of MLH-l and MLH-2 species. The 
splitting of the curves at low pH for different metal to ligand ratios is due to 
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Figure 3.9 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1:1(0), 1:2(0) and 1:3(':\), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.OOOSO 
mol dm-3) - L(O.00109 mol dm-3)] as a function of pH for ligand PrDM with Ni(II). 
Moreover, the potentiometric data analysis generated two models similar to 
that of Ni(II)-PrDH system and these models are presented in Table 3.3. Both 
models gave well superimposible theoretical and experimental formation and 
deprotonation functions as well as low standard deviation and Hamilton 
R-factors. The model with the MLH species is chosen based on the splitting 












Table 3.3: log~pqr'S of PrDM with Cu(II), Ni(II), Zn(II) and Ca(II) determined at 
25°C and I = 0.15 mol dm-3 (Cr)Na+. Other symbols have their usual meaning as 
defined in Table 3.1. 
Ligand Metal pq r Logllpqr opqr RH RlimH n,{np) 
ion 
PrDM Cu(II) Modell 
111 12.252 0.756 0.018 0.012 6(486) 
110 7.839 0.013 
1 1-1 0.829 0.017 
1 1-2 -8.185 0.020 
Model 2 
110 7.833 0.015 0.018 0.012 
1 1-1 0.806 0.016 
1 1-2 -8.193 0.019 
2 1-2 -2.948 0.308 
Model 3 
110 7.850 0.013 0.017 0.012 
1 1-1 0.717 0.019 
1 1-2 -8.255 0.019 
2 1-3 -9.322 0.099 
Ni(II) Modell 
111 11.219 0.070 0.015 0.011 6(222) 
1 1-1 -4.986 0.018 
1 1-2 -13.942 0.014 
Model 2 
110 2.168 0.382 0.015 0.012 
1 1-1 -5.050 0.018 
1 1-2 -13.986 0.013 
Zn(II) 1 1 1 12.270 0.034 0.019 0.012 6(491) 
1 1 0 3.657 0.027 
1 1 -1 -4.448 0.041 
1 1 -2 -13.082 0.042 
CaCH) 1 1 1 i 11.424 0.054 0.015 0.010 6(463) 
1 1 0 2.837 0.045 
The formation function for the Zn(II)-PrDM system in Figure 3.10(a) levels at 
pL ::; 4.5 (high pH). As also seen from the speciation graphs in Figure 3.10(c), 











shows that complexation commences at pH 4.5 when MLH species is being 
formed. The data analysis by ESTA programs gave results for the model 
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Figure 3.10 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1:1(0), 1:2(0) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.00047 
mol dm-3) - L(O.OOlOO mol dm-3)] as a function of pH for ligand PrDM with Zn(II). 
Like in Ca(II)-PrDM, the Ca2+ has low but measurable affinity for the donor 
atoms of PrDM. This is observed from Zwbar and Qwbar functions shown in 
Figure 3.11(a) and 3.11(b) respectively. The speciation graphs in Figure 
3.11(c) show species formed by the complexation of PrDM with Ca(II). The 











deprotonation functions as well as low standard deviations and Hamilton 
R-factors confirm the validity of this model. 
2 
i> 











1.5 - CI) .. 
nI 










4 5 6 7 8 9 10 11 5.5 6.5 7.5 8.5 9.5 10.5 
pH pH 
(b) (e) 
Figure 3.11 (a): Formation function and (b): deprotonation function curves [with 
1"1:L ratios 1:1(0), 1:2(0) and 1:3(i1), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.OOOSO 
mol dm-3) - L(O.00100 mol dm-3)] as a function of pH for ligand PrDM with Ca(II). 
3.5.2.3 M2+ -PrDPr 
The complexation of PrDPr with Cu(II) seems to be different from that of the 
PrDH and PrDIVl systems as observed from the formation and deprotonation 
functions in Figure 3.12(a) and 3.12(b) respectively. The Zwbar curves level 











splitting of the curves for different metal to ligand ratios is due to the 
presence of MLH. The fanning of Zwbar is indicative of hydroxo and/or mixed 
hydroxo species. Since a complete deprotonation (n-bar = 0) of PrDPr occurs 
at pH 6.2, the metal assisted deprotonation of the amide is likely to occur 
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Figure 3.12 (a): Formation function and (b): deprotonation function curves [with 
fVl:L ratios 1:1(0), 1:2(0) and 1:3(.1), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.OOOSl 
mol dm-3) - L(O.00101 mol dm-3)] as a function of pH for ligand PrDPr with eu(II). 
On the other hand Qwbar rises vertically at pH 2.5 revealing that 
complexation occurs at the very beginning of the titrations. In fact the 
speciation graphs in Figure 3.12(c) show that fVlLH is already formed (18% 











2.8 - 3.8 indicating no further complexation in this pH span. Another rise is 
observed at pH range 3.8 - 4.8 due to the formation of MLH-l species and 
hydroxo species formed at pH > 4.8. Despite the split of the curves at 
different metal to ligand ratios due to the formation of MLH species, the 
theoretical and experimental formation and deprotonation functions have 
excellent agreement. This lends confidence to the selected model. The low 
standard deviations and Hamilton R-factors presented in Table 3.4 with 
corresponding formation constants confirm this model. 
Table 3.4: log~pqr\s of PrDPr with Cu(II), Ni(II), Zn(II) and Ca(II) determined at 
25°C and I = 0.15 mol dm-3 (CnNa+. Other symbols have their usual meaning as 
defined in Table 3.1. 
Ligand Metal p q r Log (3pqr opqr RH RlimH nT(np) 
ion 
PrDPr Cu(II) 1 1 1 8.421 0.032 0.012 0.012 6(518) 
1 1 0 4.344 0.032 
1 1 -1 0.575 0.021 
1 1 -2 -4.679 0.028 
Ni(II) 1 1 1 7.701 0.077 0.027 0.021 6(546) 
1 1 0 3.688 0.041 
1 1 -1 -2.653 0.035 
1 1 -2 -9.839 0.032 
Zn(II) 1 1 1 6.903 0.038 0.011 0.012 6(518) 
1 1 0 2.764 0.036 
1 1 -1 -3.903 0.026 
1 1 -2 -10.983 0.014 
Ca(II) 1 1 1 6.612 0.041 0.024 0.011 6(456) 
1 1 0 2.460 0.131 
The complexation behaviour of PrDPr with Ni(II) and Zn(II) are the same as 
revealed by the formation and deprotonation functions in Figure 3.13 and 
3.14 respectively. At pL 6, Zwbars rise to :::: 0.1 before falling to zero after 
which they rise again to Zwbar :::: 0.5. This manoeuvre is also observed in the 
Qwbar curves. However, the percentage formation of species for the Ni(II)-











shown in Figure 3.12(c) and 3.13(c) respectively. The formation constants for 
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Figure 3.13 (a): Formation function and (b): deprotonation function curves [with 
IVI:L ratios 1:1(0), 1:2(0) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.OOOSO 
mol dm-3) - L(O.00101 mol dm-3)] as a function of pH for ligand PrDPr with Ni(II). 
There is little or no interaction between Ca(JI) and PrDPr in solution as 
observed from Zwbar and Qwbar functions in Figure 3.1S(a) and 3.1S(b) 
respectively. The species formed do not exceed 20% formation as seen in 
Figure 3.1S(c) and the solution is mainly dominated by free Ca2+ ions in the 
pH investigated. However, the stability constants for all the species are 
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Figure 3.14 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1: 1(0), 1:2(0) and 1:3(~), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.00047 





















































Figure 3.15 (a): Formation function and (b): deprotonation function curves [with 
M:L ratios 1:1(0), 1:2(¢) and 1:3(1'1), and theoretical (solid line) curve.] against pL 
and pH respectively and (e): calculated species distribution graphs [with M(O.OOOSO 
mol dm-3) - L(O.00100 mol dm-3)] as a function of pH for ligand PrDPr with eaCH). 
3.5.2.4 Discussion - Complexation 
The ligands in this study are based on the pyridine-2,6-dicarboxamide moiety 
(Figure 3.16) and this contains two ethylene linkages. Once deprotonated the 
pyridine-2,6-dicarboxamido unit should be strictly planar and maintains 
planarity in various metal complexes.4o-42 The basal plane is defined by the 
I\lamido-Npy-Namido coordination by the planar pyridine-2,6-dicarboxamido 
portion of the ligand. The central pyridine nitrogen acts as an anchor for 
amide coordination. It is also the first one to be coordinated to the metal ion 











Figure 3.16: Pyridine-2,6-carboxamide unit 
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On the basis of the selected equilibria presented in Table 3.2-3.4 and Figure 
3.4-3.15, the proposed structures for various species have been postulated 
and presented in Figure 3.17. The comparison of the formation constants for 
the mononuclear ML species of PrDH, PrDM and PrDPr with Cu(II) reveals 
that the ML species of Cu(II)-PrDH system has the greatest stability. This is 
probably due to less steric hindrance as different (-bulky) groups are 
introduced at the terminal sites. The value of IOg~110 for the Cu(II) complex of 
PrDH (=8.686) is 0.847 log units higher than that of PrDM (=7.839) and 
4.342 log units higher than that corresponding constant of PrDPr (=4.344). 
Jackson and co-workers43 have reported 10g~l1o values in the range 9.22 -
10.77 for four related dioxo-penta nitrogen donor ligands, L3c - L3f, (Figure 
3.18). The decrease in stability in the present study is due to the 
incorporation of the less basic or rather acidic pyridyl groups in the ligands. 
The proposed structures of the MLH species for ligands in the present study 
are given in Figure 3.17(a,b). The MLH species is formed by the 
deprotonation and coordination of the central pyridyl nitrogen and one of the 
terminal amino/pyridyl nitrogens as well as coordination of one or both 
carbonyl oxygen(s) to the metal ion. Between the two structures, (a) seems a 
more likely coordination geometry. The coordination geometry of structure 
(b) may be destabilized by the rigidity of the pryridine moiety of the ligand in 
allowing both carbonyl oxygens coordination. It is expected that as the pH 
increases, Cu(II) would induce ionization of the amide protons27,28 and there 
would also be a transition from Cu-O to Cu-N in the coordination 
arrangement.44 The ML species is formed by the deprotonation of the MLH 
species and the possible structures of this species are given in Figure 3.17(c-
f). The infrared study by Steenland and co-workers32 on the coordination of 
Cu(II) by dioxo-pentaaza macrocycles, L3a - L3b, (Figure 3.18) in aqueous 
solution showed absorptions attributed to amide coordination to Cu(II) 
through the carbonyl oxygen in the MLH and ML species. From the four 
structures, (d) is highly strained due to the three contiguous five-membered 











rings respectively. The rigidity of the pyridine moiety would also destabilize 
structures (c) and (e) upon coordination of Cu{II) through the carbonyl 
oxygens. Structure (f) is favoured due to the stable 5,5 membered rings. 
The pKa (log~110 - IOg~11-1) values for the conversion of ML to MLH-l species 
for the Cu{II) complexes of PrDH, PrDM and PrDPr are 6.168, 7.01 and 3.769 
respectively. Steenland and co-workers32 measured pKa (log~l1o - IOg~11-1) 
values of 3.9 and 6.8 for the dioxo-pentaaza macrocycles while Jackson and 
co-workers43 measured values in the range 7.03 - 8.13 for the linear dioxo-
penta nitrogen donor ligands. The possible structures for the MLH-l species 
are given in Figure 3.17{g-i). The structure (g) indicates that both amides are 
coordinated while one terminal amino/pyridyl group remains protonated. 
Brooker and co-workers4s reported similar structures for Cu{II) with dioxo-
penta nitrogen donor ligands. However, this structure is highly strained due to 
the three contiguous five-membered rings. Structure (h) has a less strained 8 
membered ring and this makes (h) to be preferred over (g). Structure (i), 
where the amide and the carbonyl oxygen are coordinated to the metal ion 
while the terminal arnino/pyridyl group is not, is unlikely. 
The MLH-2 species forms from the deprotonation of MLH-l species with pKa 
(IOg~11-1 - IOg~11-2) values 10.157, 8.972 and 5.254 for Cu{II) with PrDH, 
PrDM and PrDPr respectively. These PKa's are slightly higher than the 
corresponding first protonation constants of the free ligands. This proton 
could come from the coordinated water molecule or the coordinated amide 
nitrogen. The postulated structures of the MLH-2 species are given in Figure 
3.17{j-1). The structure (j) has the uncoordinated terminal amino/pyridyl 
group while (I) has uncoordinated pyridine nitrogen. The structure (I) is less 
favoured over (j) due to the large 8 membered chelate ring. Structure (k) has 
all nitrogen atoms coordinated to the metal ion making this species to be 
more strained. The possible geometry of the MLH-2 species of the Cu{II) 
complexes are of distorted square pyramidal and distorted octahedral 











and M2LH-3 species are given in Figure 3.17(m) and 3.17(n) respectively. 
These polynuclear species are only found in the complexation of Cu(II) 
especially with PrDH and PrDM. These species are likely to be formed at low 










Figure 3.18: Schematic representation of ligands discussed in this chapter. 
The formation equilibria for Ni(II), Zn(II) and Ca(II) show that these metal 
ions also form relatively stable complexes with PrDH, PrDM and PrDPr. 
However, it is observed that Cu(II) forms more stable complexes than these 
metal ions. For example, the stability constants (logWs) of the ML species of 
PrDH with Cu(II), Ni(II), Zn(II) and Ca(II) are 8.686, 6.079, 4.293 and 3.007 
respectively. The difference in stability of some 4-5 log units is observed 
between Cu(II) and the in vivo competitors Zn(II) and Ca(H). Unlike PrDH 
and PrDPr, the stability constant of the ML species of Zn(H)-PrDM 











contrary to the Irving-Williams series.46 This is also evidenced by the 
corresponding formation and deprotonation function curves as shown in 
Figure 3.10(a,b) and 3.9(a,b). Amongst the four metal ions, Ca(H) forms 
weak complexes with all the ligands. Furthermore, Ca(H) does not induce 
amide deprotonation except for the PrOH system. It is observed that the 
stability of the M-L complexes is in the order M(H)-PrOH > M(H)-PrOM > 
M(H)-PrOPr. This is due to the different basicities of the terminal N-donor 
groups which is in the order -NH2 > -N(CH3h > -Py. 
For the complexation of PrOH with Ni(II) and Zn(II) for the formation of the 
fVILH-l species by the deprotonation of ML, the calculated pKa (IOg[3110 - 10g[311-
1) values are 8.083 and 7.711 respectively. Like the CU(H)-PrOH system the 
MLH-l species predominates over a wide range of pH 7-11. Similarly the metal 
assisted deprotonated MLH-l species of PrOM with Ni(II) and Zn(II) has pKa 
values of 7.218 and 8.105 respectively. For Ni(II), the calculated pKa values 
for the formation of the MLH-l species of both PrOH and PrOM are 1.8-2.6 log 
units lower than the first and second hydrolysis constants of Ni(II) (pKM-OH = 
9.86 and 9.14). On the other hand the pKa values of the formation of MLH-1 
species for Zn(II) with PrOH and PrOM are 1-1.5 log units lower than the first 
hydrolYSiS constant of Zn(II) (pKM-OH = 9.17). For the formation of the neutral 
MLH-2 species the calculated pKa (IOg[311-1 - IOg[311-2) values are lower than the 
first hydrolysis constants of the metal ions for both ligands. However, direct 
evidence for the amide proton dissociation on complexation has been 
obtained from aqueous (020) infrared studies for Cu(II) and Ni(II) complexes 
in solution.32,47 
The low formation constants of the fVILH-l and MLH-2 species of the Zn(II) 
complexes as compared to those of Cu(H) and Ni(II) are due to the lesser 
ability of Zn(II) to deprotonate the amide mOieties.48 It is known that Zn(II) 
prefers a tetrahedral geometry as observed with the majority of its simple 
systems.49,SO It has been reported that the linear and macrocyclic dioxo-tetra 











Ni(lI) in solution while macrocyclic dioxo-penta N-donor ligands form square 
pyramidal or distorted octahedral coordinate geometry. 51-53 For the distorted 
octahedron, four nitrogen atoms are bound in the plane whereas the fifth 
nitrogen and water molecule occupy the axial positions. However, it was also 
observed that Cu(ll) forms more stable complexes with tetra I\l-donor ligands 
than penta N-donor ligands.52 
Brooker and co-workers45,54 have designed and studied 2,6-bis(1-
propanecarboxamido-3-amino)pyridine, L3h, (Figure 3.18) in solid state and 
solution for Cu(ll) and Ni(ll) complexation. This ligand is analogous to PrDH 
and PrDM. Cu(ll) formed a square pyramidal complex with four basal plane 
nitrogen donor atoms and an apical site occupied by an oxygen donor from 
acetate ion. On other hand, Ni(ll) formed square planar geometry with four 
coordinated nitrogen donor atoms. Of interest is to observe that the 
uncoordinated terminal amino group is protonated while both amides are 
coordinated. This is also observed for both PrDH and PrDM with Cu(II) 
whereby the MLH-l species forms at low pH (pH 5.5). This is indicative of the 
ability of Cu(ll) to deprotonate the amide groups and also that the central 
pyridine nitrogen plays a major role as an anchor for the metal coordination. 
At high pH the terminal amino groups would be deprotonated thus forming 
MLH-2 species. 
The coordination chemistry of PrDPr with Cu(lI) Ni(ll) and Zn(ll) has been 
studied in solid state.42,55 This ligand is found to form a binuclear structure of 
[Cu2(PrDPrhJ as a major complex and monomeric CuPrDPr as a minor 
complex. Ni(ll) and Zn(ll) form trinuclear complexes as major species. 
However, the minor monomeric species of the metal ions suggested four N-
donor coordination arrangements with uncoordinated terminal pyridine 
groups. The present study of PrDPr with Cu(ll), Ni(lI) and Zn(II) indicates 
that four different mononuclear species are formed in solution. The MLH-1 and 
MLH-2 species form at low pH and the speciation graphs show that there is 











incorporation of the pyridyl groups which tend to coordinate to metal ions at 
low pH. The calculated pKa (IOg~111 - IOg~110) values (~4) of the formation of 
the ML species are close to the first and second protonation constants of the 
ligand (PKal == 4.624 and PKa2 == 3.508) for all the four metal ions investigated. 
The deprotonation of the amide groups results in the formation of the MLH-l 
and MLH-2 species for all metal ions except Ca(II). These species are formed 
below and/or at physiological pH. The calculated pKa (lOg~110 - IOg~l1-lt 
IOg~1l-1 - IOg~11-2/) values of the formation of these species are lower than the 
first and second hydrolysis constants respectively of the corresponding metal 
ions. 
Table 3.5: Selectivity factors of the studied ligands towards Cu(ll) compared with 
the other investigated metal ions. 
Ligand Cu(II)/Ni(II) Cu(II)/Zn(ll) Cu(Il)/Ca(II) 
~ ... 
PrOH 4.336 5.936 11.384 
PrOM 6.703 5.165 
PrOPr 3.228 4.478 
The metal ion selectivity of a ligand is generally defined as the difference in 
the formation constants of the complexes formed with all metal ions likely to 
be present under the same conditions of pH.56,57 In this study the selectivity 
of Cu(ll) is defined as the difference in formation constants of [CuLH-1] with 
that of the corresponding species for a particular M-L system. The MLH-l 
species has been chosen because it forms at the physiological pH for Cu(ll) 
with PrDH, PrDM and PrDPr. The calculated selectivity factors given in 
Table 3.5 indicate that the studied ligands are more selective for Cu(ll) as 
compared to NiCII), Zn(ll) and CaCll). The calculated selectivity factors are in 
the range of 3-11 orders of magnitude in favour of Cu(ll). The higher 
formation constants of Cu(ll) with these ligands are due to the ease with 
which this metal ion deprotonates the amide groups. The selectivity factors 











that has the order Cu(II)/Ni(II) > Cu(II)/Zn(II) which contradicts the Irving-
Williams series.46 However, the selectivity demonstrates favourable 
complexation for Cu(II) by these ligands relative to the in vivo competitors, 
Zn(H) and Ca(H). The in vivo Zn(II) and Ca(II) ions are present in high 
concentrations and therefore, could upset the favourable selectivity for Cu(II). 
Moreover, the favourable selectivity for Cu(II) over these metal ions is 
brought about by the preferred tetragonally distorted geometry due to the 
ligand field Jahn-Teller distortion. This is observed in the copper-carrying 
plasma protein, albumin, whereby peptide nitrogens are ionized and Cu(II) 
bonds in roughly square planar fashion to four nitrogens.58 A further study on 
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4. SPECTROSCOPY AND MOLECULAR MODELLING 
4.1 NUCLEAR MAGNETIC RESONANCE 
4.1.1 Introduction 
Nuclear magnetic resonance (NMR) is an important tool in the investigation of 
chemical structures and reaction mechanisms. It has been extended to whole 
body imaging in medical diagnosis. 1 In this study NMR is used to determine 
the sequence of protonation of PrDH, PrDM and PrDPr. The presence of the 
proton is expected to shift the NMR signals arising from protons attached to 
the neighbouring carbons. It has also been used to gain some insights as to 
the site of metal coordination as upon complexation by Cu(II), the presence 
of the metal ion is expected to broaden and shift the signals arising from 
protons attached to neighbouring carbons being most affected.2 
4.1.2 Experimental 
In 5 cm3 glass Vials, two cm3 portions of 0.015 mol dm-3 stock D20 solution of 
PrDH, PrDM and PrDPr were prepared and the IH NMR spectra recorded on a 
Varian Unity Plus 400 MHz instrument. The pH of the solutions was adjusted 
using concentrated NaOH and HC!. Tertiary butyl alcohol was used as an 
internal reference. A micro-pH 2000 meter was used to measure the pH of 
the solutions. Solutions of 1:2 molar ratio of the metal to ligand for Cu(II)-
PrDH, Cu(II)-PrDM and CU(II)-PrDPr systems were prepared in D20 and 











4.1.3 Results and discussion 
4.1.3.1 Cu(II)-PrDH system 
Figure 4.1(a) shows proton NMR spectra for the protonation of PrDH in D20. 
As the pH of the solution increases, some of the NMR signals shift up field. 
The shift is a result of protonation, the protons closest to the site of 









10 8 6 4 
I I I 
2 ppm 0 
Figure 4.1(a): Proton NMR spectra of PrDH as a function of pH. 
Figure 4.1(b) shows a plot of proton chemical shifts as a function of pH, 
where a, band c,d refer to the chemical shifts of the protons attached to 











carbons of the pyridine ring respectively. There is a small change in the 
chemical shift of the c,d-protons as compared to the a- and b-protons. 
However, a noticeable change is observed at pH value of about 2 due to the 
deprotonation at the pyridyl nitrogen. The plots of change in proton chemical 
shift show approximate pKa values of about 2 and 9 which are in good 
agreement with the values obtained from potentiometric studies. 
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Figure 4.1(b): Change in proton chemical shift (ppm) as a function of pH for PrDH 
system. 
Figure 4.1( c) shows the effect of Cu(II) upon the spectra of PrDH as a 
function of pH. Since Cu(II) is paramagnetic, it tends to broaden and shift the 
signals arising from protons attached to neighbouring carbons as observed in 











the free ligand starts at pH 5 and, therefore a change in NMR spectra signals 
is expected at pH>5. The signals a, band c,d in Figure 4.1(c) broaden and 
shift as pH increases. The signal arising from protons attached to carbons 
next to the amine groups virtually disappear at pH 6.69 due to the closeness 
of the Cu(II) ion. These two possibilities cannot be distinguished as the 
system is in rapid chemical exchange on the NMR time scale. This indicates 
that either one or both amine groups are coordinated to the metal ion. The 
signals arising from protons attached to carbons next to the amide groups 
also broaden and shift to up field. This is indicative of coordination of the 
metal ion to at least one amide group as pH increases. It is also observed that 
protons (c,d) at the carbons of the pyridine ring virtually disappear due to the 
closeness of the Cu(II) ion coordinated to the pyridyl nitrogen. From these 
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Figure 4.1(c): Proton NMR spectra for complexation of Cu(II) with PrDH as a 











4.1.3.2 Cu(U}-PrDM system 
Figure 4.1(d) shows proton NMR spectra for protonation of PrDM. Like for the 
PrDH system, there is shift in NMR signals to up field as the pH increases due 
to protonation of the terminal amino and pyridyl nitrogen groups. A significant 
chemical shift is observed for protons attached to carbons next to the amino 
groups at pOSitions, a and b. It must be noted that the signal due to a-
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Figure 4.1(d): Proton NMR spectra of PrDM as a function of pH. 
; 
Figure 4.1(e) shows plots of proton chemical shifts as function of pH, where 
a, b, c and d,e refer to the protons attached to carbons on the ligand in 











neighbouring carbons is similar to that of the PrDH system except that there 
is an additional signal arising from a-protons of the terminal methyl groups. 
The approximate pKa value of 8.5 is in good agreement with the value of 
8.647 obtained by potentiometric studies. 
Figure 4.1(f) shows the spectra for complexation of Cu(II) with PrDM as a 
function of pH. Like for the Cu(II)-PrDH system, NMR signals arising from 
protons attached to neighbouring carbons broaden and shift to up field due to 
complexation. Complexation of the free ligand starts at pH 5 as shown by the 
species distribution curves in Figure 3.8(c). The change in I'JMR spectra 
signals is similar to that of the Cu(II)-PrDH system indicating that indeed 
complexation takes place at all the nitrogen centers. 
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Figure 4.1(f): Proton NMR spectra for complexation of Cu(II) with PrDM as a 
function of pH. 
4.1.3.3 Cu(II)-PrDPr system 
The I\lMR spectra showing the protonation of PrDPr is shown in Figure 4.1(g). 
Unlike the other two systems, protonation of the PrDPr system begins at low 
pH as shown in Figure 3.3(b). The proton I\lMR signals show significant 
differences in chemical shift at pH 3.31 and 4.04 (Figure 4.1(g)) as a result of 
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Figure 4.1(g): Proton NMR spectra of PrDPr as a function of pH. 
Plots of chemical shift in Figure 4.1(h) arise from protons attached to the 
pyridyl nitrogens and amide groups. Like other two systems in this study, the 
NMR signals shift to up field as the pH increases. Figure 4.1(i) shows spectra 
for the complexation of Cu(II) with PrDPr. The spectra show that there is 
complexation at pH 1.60, and NMR signals broaden and shift to up field as the 
pH increases. All signals virtually disappear at pH 4.86. This is indicative of 
the closeness of Cu(II) to the pyridyl and amide nitrogens. The speciation 
graphs in Figure 3.12( c) also show that there is already complexation at pH 
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Figure 4.1(i): Proton NMR spectra for complexation of Cu(II) with PrDPr as a 
function of pH. 
4.2 INFRARED SPECTROSCOPY 
4.2.1 Introduction 
Infrared (IR) is an important tool in the investigation of chemical structures. 
IR spectra originate from transitions between two vibrational levels of the 
molecule in the electronic ground state and are usually observed as 
absorption spectra in the infrared region. 3,4 In this study IR is used to 
establish the involvement of the amide oxygen or nitrogen donor in the 












In 5 cm3 glass vials, two cm3 portions of 0.1 mol dm-3 stock D20 solutions of 
PrDH, PrDM and PrDPr were prepared and IR spectra recorded at 25°C on a 
Perkin Elmer Spectra One FT-IR spectrometer (Overhead - ATR ZnSe top 
plate). The pH of the solutions was adjusted using NaOD and DCI. A micro-pH 
2000 meter was used to measure the pH of the solutions. Solutions of 1: 1 
molar ratio of the metal to ligand for Cu(II)-PrDH, Cu(II)-PrDM and 
CU(II)-PrDPr systems were prepared in D20 and scanned in the pH range 
1-12 in the wavenumber region 1400 and 1700 cm-l . 
4.2.3 Results and discussion 
4.2.3.1 Cu(U)-L systems 
Figure 4.2(a) shows IR spectra of PrDH in D20 solution. The protonated 
ligand shows a significant absorption band at 1651 cm-l which shifts to 
slightly lower frequency upon neutralization. This band can be assigned to the 
asymmetric amide carbonyl stretching vibration in the ligand. Upon 
complexation by Cu(II), this band broadens and almost disappears at pH 
11. 72 as shown in Figure 4.2(b). At pH 4.05, there are two observable bands, 
1571 and 1590 cm-l . The intensity of the absorption band at 1571 cm-l 
increases with increasing pH until at pH 6.92 where it is replaced by the band 
at 1565 cm-l at higher pH. This is indicative of loss of protons from the amide 
group(s) due to complexation. The band at 1590 cm-1 is replaced by two 
bands, 1582 and 1594 cm-l at pH > 4.87. This shows that coordination to 
amide nitrogens starts at an early stage. This is also observed in the 
potentiometric results (section 3.5). Other bands observed in these spectra 
are the same as those of the ligand in the absence of Cu(ll). 
Figure 4.2(c) and 4.2(d) show IR spectra of PrDM and Cu(Il)-PrDM in D20 











stretching vibration in the ligand. Along with a slight shift to lower frequency, 
this band broadens and almost disappears at higher pH due to complexation 
by Cu(II). There are two absorption bands observed at 1571 and 1590 cm-1• 
These bands behave the same way as those of the Cu(II)-PrDH system. The 
emergence of absorption bands at 1566, 1582 and 1594 cm-1 is the results of 
coordination of the amide nitrogens to Cu(II). Martell and co-workersS,6 
studied peptide carbonyl groups of glycine derivatives and Cu(II) using IR 
technique. The results showed metal-peptide nitrogen coordination for the 
metal chelate species in solution. It was observed that when the two peptide 
hydrogens are displaced from the complex, the absorption bands of the two 
peptide carbonyl groups shift to lower frequency due to resonance that occurs 
in the amide groups. The resonance is formed when a peptide proton is 
displaced and thus considerably lowering of carbonyl bond order occurs. 
The results of the CU(II)-PrDPr system in Figure 4.2(f) show that 
complexation starts at an early stage. This was also observed in the 
potentiometric results (section 3.5). The absorption bands at 1564, 1591, 
1656 and 1679 cm-1 broaden and the intensity of these bands increases with 
pH. The observed two bands at 1565 and 1568 cm-1 in Figure 4.2(e) in the 
free ligand is replaced by one band at 1565 cm-1 with shoulder at 1556 cm-1 
upon complexation by Cu(II). It was expected that complexation would 
commence at low pH due to the incorporation of the pyridyl groups in the 
PrDPr. It was also expected that the central pyridyl nitrogen would coordinate 
to Cu(II) first, thus enhancing ionization and coordination of the neighbouring 
amido groups. 
In the study of Cu(II) complexes of macrocyclic ligands in aqueous solution 
by 5teenland and co-workers7,8, coordination of the amide to Cu(II) through 
the carbonyl was observed. In the present study, there were no distinct bands 
showing absorptions due to the coordinated carbonyl oxygens. The 
coordination of the carbonyl oxygen to Cu(II) in the formation of MLH and ML 











the anchoring of the pyridyl nitrogen would induce ionization of the amide 
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4.3 UV - VISIBLE SPECTROSCOPY 
4.3.1 Introduction 
Transition metal complexes give rise to a fascinating variety of colours. These 
colours come from electronic transitions between energy levels whose 
spacings correspond to the wavelengths of visible light. In complexes, these 
transitions are frequently referred to as d-d transitions because they involve 
molecular orbitals that are mainly metal d in character. Since this spacing 
depends on factors such as the geometry of the complex, the nature of the 
ligands present, and the oxidation state of the central metal atom, electronic 
spectra of complexes can provide valuable information related to bonding and 
structure.9 As a result, UV-visible spectrophotometry is used as a 
supplementary technique to glass electrode potentiometry when ionic 
equilibria are investigated. 
UV-visible spectrophotometry provides an additional method for comparing 
possible chemical models not available with potentiometry. However, because 
the UV-visible spectra of most complexes contain broad overlapping 
absorption bands, parameter correlation arises and therefore, it is not usually 
possible to evaluate stability constants as preCisely from spectrophotometric 
data as compared to potentiometric data. The potentiometric data may lead 
to a more precise analysis of the wrong model, whereas spectrophotometric 
data will indicate the correct model but give a less precise analysis of it. 
Therefore, it is necessary to combine both spectrophotometriC and 
potentiometric data for defining the chemical model and for evaluation of the 
stability constants respectively.lO 
4.3.2 Electronic Spectra of Metal Complexes 
The relative intensities of electronic transitions are governed by a series of 











those with a change of parity, gerade to ungerade (g -+ u) and ungerade to 
gerade (u -+ g) but not g -+ g or u -+ u. This would mean that all d-d 
transitions in octahedral complexes are formally forbidden. Another rule states 
that transitions between states of different spin multiplicities are forbidden. 
For example, a if configuration in an octahedral field would have three 
transitions that are spin allowed; 37jg -+ 3T2g, 37jg -+ 3 A2g, 37jg -+ 37jg. 
However, there are mechanisms by which these selection rules can be relaxed 
so that transitions can occur, even if only at low intensities. The bonds in 
transition metal complexes are not rigid but undergo vibrations that 
temporarily change the symmetry of the molecule. Therefore, d-d transitions 
of octahedral complexes result in low-intensity spectra. Tetrahedral 
complexes often absorb more strongly than octahedral complexes of the 
same oxidation state. The spin selection rule breaks down somewhat in 
complexes that exhibit spin-orbit coupling. This results in bands associated 
with formally spin forbidden transitions gaining enough intensity to be 
observed. The spin-orbit coupling and Jahn-Teller distortions often lead to 
more complex spectra than predicted with the spin selection rule.9,11,12,13 
4.3.2.1 Copper complexes 
Many inorganic complexes including copper complexes absorb in the visible 
region (400 - 700 nm). The chemistry of the copper(II) ion differs from that 
of the copper(I) ion in that while the latter has a closed shell configuration 
(Ar)do and forms diamagnetic and colourless complexes, the former has an 
incomplete d shell configuration (Ar)cf and its complexes are predominantly 
paramagnetic and highly coloured. 14 The aqueous chemistry of copper is 
largely devoted to copper(II) compounds because copper(I) compounds are 
quite unstable in aqueous solution. Although Cu2+ can be dealt with as the 
equivalent of a one-electron case, the detailed interpretation of its spectra 
and magnetic properties can be somewhat complicated. However, copper(II) 












Most copper(II) complexes and compounds have a distorted octahedral 
structure. These compounds absorb in the region 11,000 - 16,000 cm-1 and 
show broad absorption band corresponding to the three overlapping 
transitions 2A19 +-- 2819, 2829 +-- 2819 and 2Eg +-- 2819 which are spin-allowed. 
However, octahedral complexes of copper(II) are appreciably distorted due to 
the Jahn-TeHer effect and so there is more than one peak. These peaks 
overlap forming a broad and unsymmetrical band. The octahedral 
arrangement causes crystal field splitting of the d orbitals on copper into 
lower energy eg and high energy t2g levels. The nine d electrons are arranged 
(egj and (t2g/. Since the eg level is not symmetrically filled, Jahn-Teller 
distortion occurs. Thus the complex is distorted.ll 
Aqueous Cu2+ forms many complexes with ammonia and ammines such as 
[Cu(H20)sNH3f+, [CU(H20)4(NH3hf+, CU(H20)3(NH3h]2+ and 
Cu(H20)2(NH3)4f+, It is difficult to add a fifth or sixth NH3, though it is 
possible to make [Cu(NH3)6]2+ using liquid ammonia as a solvent. The value 
of 110 (the d orbital ligand field splitting) for the hexammine copper(II) 
complex is found in the range 10,200 - 10,700 cm-1. The ligand strengths of 
amines towards copper(II) are in the order NH3 > RNH2 > R2NH > R3N. In 
aqueous solution the Cu2+ ion has absorption and magnetic spectra which can 
be interpreted in terms of the tetragonally distorted [CU(H20)6f+ ion, the 
value of 110 being 12,500 cm-l,lS The ligand field strength of water compared 
to other donors is shown by the order CI < H20 < pyridine < NH3 < 1,2-
diaminoethane. 
Several complexes of copper(II) with polydentate ligands containing nitrogen 
have been studied and the type of complex formed by copper(II) with these 
ligands depends on both the number of the donor atoms and the steric 
requirements of the ligand molecule. is Copper(II) peptide complexes have 
been studied as models for copper(II) - protein interactions. It was observed 











ionized from peptide nitrogen atoms. Other biologically important donor 
atoms such as N(amino), N(imidazole), O(carboxylate), O(peptide), H20 and 
OH- have been studied.16 
The nature of electronic transitions that are brought about by chelating 
ligands can be inferred from the general observation of the effect of 
monodentate ligands on the ligand field parameter. Table 4.1 shows the 
guideline that is normally used for the estimation of the ligand field imposed 
by nitrogen-based chelating ligands. This is also relevant to the present study. 
Table 4.1: Absorption maxima of the copper(II) ammine complexes18 of the general 
formula [Cu(NH3)n(H20knf+ 







4.3.3 Data Analysis 
A solution of metal ion and ligands will normally contain a number of different 
species at different concentrations. These species will contribute to the 
absorption spectrum and thus the final spectrum will be the sum of all the 
species present. It is often difficult to obtain the spectrum of a single species. 
The Beer-Lambert-Bouger law, commonly called Beer's law, is the 
fundamental law governing the attenuation of radiation by a specific 











a solution is a linear function of the concentration of the absorbing species as 
given by;lO 
A = 10g(10/I) = £eI (4.1) 
where 10 and I are the intensities of the incident and emergent light beams 
respectively, £ the molar absorption coefficient, c the species concentration in 
mol dm-3 and I the optical path length. 
For a given concentration and path length, the actual absorbance depends on 
the molar absorption coefficient of the absorbing species of interest. 
However, for the electronic absorption spectra of solutions containing more 
than one species the Beer-Lambert law can be expanded to give linear 
combination of terms for each individual species. 
The absorbance Aobs, at wavelength A and when n species are present, is 
given by: 
(4.2) 
where £/" , £/' and £/ are molar absorption coefficients of species 1,2 and n at 
the same wavelength A, and Cl, C2 and Cn are their respective concentrations. 
If the path length is given in cm, £n" is the molar absorption coefficient of the 
nth species in solution at wavelength A and has the units dm3 mor l cm- l •l ? The 
linear dependence of AObs" on the concentrations of various species present is 
an important feature in the equation. If a certain species has a value of £" 
equal to zero, then it does not absorb in the chosen spectral region and 
therefore does not influence AObS" . 
Complexometric titration solutions may be made up of a number of solutions 
of different metal and ligand concentrations, and pH. If the UV-visible spectra 











of the individual species can be calculated by solving a set of linear equations 
(equation 4.2). It is recommended that adjustment of pH of the metal-ligand 
complex solution be made using strong acids and alkalis such as HCI and 
NaOH which do not absorb appreciably in the spectral region of interest. 
Calculation of £ can be done using a specially designed computer program 
that requires an input file with all the information relevant to the chemical 
system being studied. The information includes amongst other parameters 
such as the concentration values of each chemical species present in the 
reaction. These concentration values are calculated on the basis of the 
stability constants obtained from glass electrode potentiometry. The values of 
£ are then plotted against wavelength to give a spectrum showing the 
absorption bands of each chemical species. Since the data is analyzed 
independently at each wavelength the existence of a smooth spectrum is not 
inherent in the data analysis and so if one is obtained it lends confidence to 
the experiment. If the stability constants and hence the concentrations are 
not correct, the spectrum will be disjointed and this is indicative of a wrong 
chemical model. After having electronic absorption spectral information for 
each of the complex species, the nature of the ligand field environment of the 
central metal ion can be determined. 
A UV-spectra software program was developed in our laboratory in order to 
solve the expanded Beer-Lambert Law equation. The program deconvolutes 
the UV jvisible titration data into the spectra of individual species. 19 
4.3.4 Experimental 
Spectrophotometric titrations were performed for Cu(II) complexation with 
PrDH, PrDM and PrDPr ligands. An aqueous solution of 1:2 metal to ligand 
ratio was prepared and measured over the pH range 2-11. Small amounts of 
0.1 mol dm-3 NaOH and 0.02 mol dm-3 HCI were used to adjust the pH during 











Spectrophotometric measurements were taken automatically at 2 nm interval 
in the wavelength range of 340 - 820 nm using a Cary 100 Conc 
spectrophotometer. 
4.3.5 Results and discussion 
Colour changes were noticed during the titration process of Cu(ll) with PrDH, 
PrDM and PrDPr ligands. This was a result of the changing speCiation of the 
solution with pH, forming different complex species with different absorption 
spectra. The absorption spectra were obtained in the pH range 2-11. 
4.3.5.1 Cu{U)-L systems 
Figure 4.3(a) shows the UV-visible electronic spectra of the Cu(II)-PrDH 
system as a function of pH. At pH values below 4.58, there is little complex 
formation and the spectrum is that of [Cu(OH2)6f+ with maximum absorption 
at 760 nm. As the pH increases from 4.58 to 5.34, the absorption band 
slightly shifts to shorter wavelengths and increases in intensity. The MLH 
species with maximum wavelength ("-max) of 590 nm and molar extinction 
coefficient (E) of 7.1 dm3 mOrl cm-l, seems to predominate at this pH range 
as indicated by the potentiometric results (section 3.5). Further increase in pH 
up to a value of 7.90 causes the absorption band to increase in intensity and 
shift to shorter wavelengths due to the Cu-O to Cu-N bond rearrangement. 
From the potentiometric results, the species formed in this region are ML and 
MLH-l, and a 190 nm blue shift in the absorption maximum is due to the 
coordination of the pyridyl nitrogen, amide nitrogen and terminal amino 
group(s). The ML species exhibits "-max = 570 nm and E = 12.9 dm3 mOrl cm-1 
whereas MLH-l shows "-max = 560 nm and E = 164.9 dm3 mor l cm- l as shown 
in Figure 4.3(b). No further changes were observed in the pH range 7.90 -
10.67. The fvmax( =560) obtained from the calculated spectra for the MLH-2 
species is the same as that of MLH-l species. This suggests that there is no 











change in extinction coefficient which indicates some change in the symmetry 
of the molecule. In general the more distorted the molecule the higher the 
extinction coefficient. Therefore, a CuN4 type of coordination is most likely to 




















Q) 140 '0 
~ -;- 120 
o E 
u U 
!: -; 100 
o -._ 0 .... E 80 u 
!: ., 
:;::; E 







400 450 500 550 600 650 700 750 800 
Wavelength (nm) 
(b) 
Figure 4.3 UV-visible electronic absorption spectra for (a): Cu(II)-PrDH [with 
M(O.OOOSl mol dm-3)-L(0.00109 mol dm-3)] and (b): calculated species spectra for 
Cu(II)-PrDH in aqueous solution 
The broad absorption bands observed for the MLH, ML, MLH-1 and IVlLH-2 
correspond to the three overlapping transitions 2A19 +- 2819, 2829 +- 2819 and 











spectra lends confidence to the results obtained and also supports the 
potentiometric model used in this system. 23 
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Figure 4.3 UV-visible electronic absorption spectra for (c): Cu(II)-PrDM [with 
M(O.OOOSl mol dm-3)-L(0.00107 mol dm-3)] and (d): calculated species spectra for 
Cu(II)-PrDM in aqueous solution. 
Figure 4.3( c) shows the UV-visible electronic spectra of the' Cu(II)-PrDM 
system as a function of pH. At pH below 5.04, the complex formation is that 
of the dominant CU06 with H20 as ligands. At low pH( =5.04 and 5.53), the 
absorption band maximum increases in intensity with a slight shift to shorter 
wavelengths. As the pH is increased, the band maximum increases in intensity 











observed. Figure 4.3(d) shows the calculated species absorption spectra for 
the Cu(II)-PrDM system. A noticeable feature about these spectra is that the 
individual species spectra have high £ values as compared to those of the 
Cu(II)-PrDH system. The Amax(£) values for the ML, MLH-l and MLH-2 are 
600(123.9), 590(173.6) and 570 nm(206.3 dm3 mor l cm-l ). According to the 
speciation curves (section 3.5), these species are observed to dominate at 
different pH regions. A difference of 160 nm for the hydrated Cu(II) and IVIL 
species is indicative of the rearrangement of ligands positioned in the 
coordination sphere of the Cu(II) ion. The d-d electronic absorption band with 
Amax at 590 and 570 nm for the MLH-l and MLH-b and slightly asymmetric at 
the low-frequency side is consistent with such a tetragonal coordination 
geometry of Cu(II). 
The UV-visible electronic absorption spectra for the CU(II)-PrDPr system are 
shown in Figure 4.3(e). This system shows one absorption band. Before 
titration by the base, the complex formation has already begun (curve at pH 
2.39) and the dominant species is that of CUN2 type of coordination with 
absorption maximum at 660 nm. This is in support of the speciation curves 
(section 3.5) which show that complexation begins at pH < 2. As the pH 
increases, the band maximum shifts to shorter wavelengths and increases in 
intenSity up to a pH value of 5.81, above which a slight red shift in 
wavelength is observed. The calculated absorption spectra for the individual 
species are shown in Figure 4.3(f). These species show Amax values of 660, 
640, 630 and 650 nm with corresponding £ values of 23.8, 14.7, 91.6 and 
94.9 dm3 morl cm-1 for the MLH, ML, MLH-l and MLH-2 species respectively. 
Marlin and co-workers obtained a band with Amax at 613 nm (£ = 220 dm3 
































500 550 600 650 700 750 800 
Wavelength (nm) 
(f) 
Figure 4.3 UV-visible electronic absorption spectra for (e): Cu(II)-PrDPr [with 
M(O.OOOSl mol dm-3)-L(O.OOlOl mol dm-3)] and (f): calculated species spectra for 
Cu(II)-PrDPr in aqueous solution. 
The electronic spectra computed from the spectrophotometric titration data 
and formation constants of the different Cu(II) complexes with PrOH, PrOM 
and PrOPr in Figure 4.3(b,d,f) show smooth spectra. The PrOH and PrOM 
systems show a single broad d-d absorption band which is typical of a 
distorted tetragonal Cu(II) complex. 20 These systems are NS02 type ligands 
capable of donating five nitrogen atoms, two amino, two amido and one 











MLH-z species of the Cu(II)-PrDH whereas Cu(II)-PrDM has Amax of 590 and 
570 nm for MLH-l and MLH-2 respectively as shown in Table 4.2. The Amax of 
these two species is the same for Cu(II)-PrDH whereas Cu(II)-PrDM has a 
difference of 20 nm for the same species. Such close agreement in Amax 
values for these two species suggests that the metal ion has the same 
geometry in both species. NMR and IR studies indicate that the amide 
nitrogen takes part in the coordination sphere at an early stage (low pH). This 
is due to the incorporation of the pyridyl nitrogen functioning as an anchor for 
the ionization and coordination of the neighbouring amido group. Although 
coordination of the fifth donor atom forming a distorted square pyramidal or a 
distorted tetragonal complex is possible, it would be destabilized by the 
formation of four contigous five-membered rings. The MLH-2 species is most 
likely to be formed by coordination of one terminal amino, two deprotonated 
amido and pyridyl nitrogens to the Cu(II). 
On the other hand, the absorption maximum for the CU(II)-PrDPr system is 
somewhat red shifted as compared to those of the other two systems as 
shown in Table 4.2. This may be due to the relatively weak binding by the 
pyridyl nitrogens. There is also a red shift of 20 nm for the MLH-z species 
which may be due to coordination by the axial nitrogen donor of the fifth 
nitrogen. The Amax value of 650 nm is more consistent with that of 
[Cu(NH3)s(H20)f+.18 Thereforel this suggests that all nitrogen donors are 
coordinated to the metal ion. This is as also supported by potentiometric and 
NMR studies. 
Previous studies show that rearrangement of donor atoms in the coordination 
sphere result in the splitting or significant shift of the absorption bands.22,25 
The present study shows results similar to those obtained by Steenland and 
co-workers8 for the macrocyclic pentadentate (L3a and L3b in Figure 4.3) 
analogues of PrDH and PrDM. The coordination geometry of the MLH-2 
species in CU(II)-PrDH, Cu(II)-PrDM and Cu(II)-PrDPr systems is likely to be 











strong axial interaction from a nitrogen donor in MLH-2 would certainly shift its 
d-d absorption band to lower wavenumbers relative to MLH-l resulting from a 
weakening of the in-plane ligand field by a synergic effect.8,20 Nomkoko26 and 
Mkhomta-Gama27 also obtained similar results in the study of pentadentate 
diamide ligands (L3g and L3e in Figure 4.3). 
Table 4.2: Wavelength (nm) and molar extinction coefficient values (dm3 mor l cm- l ) 
in brackets, corresponding to maximum absorption of various Cu(II) species formed 
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Figure 4.3: Schematic representation of ligands discussed in this section. 
4.4 MOLECULAR MECHANICS 
4.4.1 Introduction 
Advances in computing have greatly increased the interest in computer-based 
molecular modelling.29,30 Computer modelling is now widely used as an aid in 
the interpretation of experimental results and in the design of new materials 
with desirable properties. Molecular mechanics (MM) is a very popular tool for 
describing the structures and relative energies of many classes of 
molecules.29,30,32 Its wide use is primarily due to computational simplicity and 
efficiency whereas quantum mechanical modelling is far more computationally 
intensive and until recently has been used only for rare metal complexes. 











(internal energy) of different possible geometries for the determination of the 
stability of related complex species in solution. 
4.4.2 Theory 
The basis of the molecular mechanics method is that a good estimate of the 
geometry of a molecule can be obtained by taking into account all the forces 
between atoms, calculated using a mechanical approach.29,30 To optimize the 
geometry of a molecule, the total energy that arises from these forces, or 
stresses, is minimized by computational methods. 
Molecular mechanics studies in both inorganic and organic chemistry define 
strain energy Utotal as arising from four principle energy terms,29,30,31 the 
general form of which is given as; 
Utotal = I (Eb + Eo + E¢ + Enb ) (4.3) 
molecule 
where IEb is the total bond deformation energy, IEo the total valence 
angle deformation energy, I E¢ the total torsional (or dihedral) deformation 
energy and I Enb the total non-bonded (van der Waals) interaction energy. 
The individual energy terms are calculated using simple functions with bonds 
modelled as springs that obey Hooke's law; 
Eb ~ Kb(rj/ + roY (4.4) 
where Kb is the force constant or spring strength and ro the ideal bond 
length or length the spring wants to be. Valence angles are modelled in a 
similar way, 
Eo = ~ Ko(Bijk + BoY (4.5) 
where Ke is the strength of the spring holding the angle at its ideal value Bo' 
Torsion or dihedral angles cannot be modelled in the same manner since a 












E¢i "2 Ke(l + cos(m(¢ijkl + ¢Offset)) (4.6) 
where Ke is the height of the barrier to rotation about the torsion angle ¢ijkl' 
m the periodicity and ¢offset the offset of the minimum energy from a 
staggered arrangement. Non-bonded interactions are calculated using a 
function that includes a repulsive and attractive (London dispersion) 
component, 
(4.7) 
where dij is the distance between the nuclei and A, Band C are atom based 
constants. 
Additional components have been added to the calculation of the strain 
energy. Out-of-plane deformation energy, E6 1 has been included in models of 
aromatic or Sp2 hybridized systems, 
(4.8) 
where 1J is the angle between the plane defined by three atoms and the 
vector from the center of these atoms to a fourth bonded atom, and ko the 
corresponding force constant. Electrostatic interactions terms E" are 
modelled based on the Coulomb law, 
(4.9) 
where qj and qj are partial charges on atoms i and j, & the dielectric 
constant and dij the interatomic separation. Hydrogen bonding interaction 
terms are generally modelled using a function of the type given as; 
E b = Fd-:.12 Gd-:.10 n lj lj (4.10) 
where F and G are empirically derived constants that reproduce the energy of 
a hydrogen bond and dij the donor-accepter distance. The addition of these 
terms gives rise to the revised definition of Utotal given as; 












The set of functions together with the collection of terms that parameterise 
them is referred to as the force field. In general force field terms are derived 
empirically with the target of reproducing experimental structures and energy 
distributions.29,30 However, the goal of molecular mechanics is to find the 
geometry with minimum strain energy. The value of the strain energy is 
dependent on the force field and therefore, 11as little meaning in absolute 
terms. The choice of the force field to study molecules containing a metal is 
not clear-cut.30,32. This is due to various factors which include the partially 
filled d-orbitals of the transition metal ions that are responsible for 
multifarious structures of coordination compounds with a large variety of 
possible coordination numbers and geometries. Moreover, the extension of 
these force fields to inorganic chemistry is a more recent 
development. 29,30,32,33,34 
In an attempt to model metal complexes, an extensible systematic force field 
was designed to model inorganic and organometallic compounds as well as 
organic and biochemical systems.35 It differs from existing force fields in both 
functional forms as well as parameterization approach. It employs semi-
emperical rules to translate atomic-based parameters to parameters typically 
associated with a covalent valence force field. The atomic parameters depend 
not only on atom type, but also on internal type, thus resulting in a more 
accurate force field. The force field has been applied to molecular simulations 
of a wide variety of systems including nucleic acids, peptides, hydrocarbons, 
porphyrins, transition metal complexes, zeolites and organometalic 
compounds. 
4.4.3 Simulations 
The MM calculations were done on a SyncMaster llOOp computer using 
InsightIl.36 The Cu(lI) complexes (schematic representation of proposed 











BUILDER module. Molecular mechanics calculations were performed using the 
Discover _3 program which was run as an application in the InsightII package. 
All calculations were done in vacuum. 
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4.4.4 Results and discussion 
The energy minimised structures for the Cu(II)-PrDH, Cu(II)-PrDM and 
CU(II)-PrDPr systems are given in Figure 4.4(2), 4.4(3) and 4.4(4) 
respectively. The output data for the deformation energies including internal 
(strain) energy for these structures is given in Table 4.3. The energy 
minimised structures are compared in terms of internal energy and not 
potential energy. The potential energy is dependent on the number of 
covalent bonds in the structure and also includes a contribution from non-
bonded electrostatic interactions, which is greatly influenced by the charge of 
the Cu(II). The internal energy which was a criterion considered for stability 
comparison, indicates the strain energy around the central metal ion. 
MLH, (a), 7,5 ML, (f), 5,5 
Figure 4.4(2): Energy minimised Cu(II) complexes showing equatorial plane 
coordination by structure (a) an amine, a pyridine nitrogen donor and a carbonyl 
oxygen donor atoms, giving a 7,5 chelate ring sequence (109.36 kcal mol-i) and 
structure (f) an amine, a pyridine nitrogen donor and an amide nitrogen donor 
atoms, giving a 5,5 chelate ring sequence (50.75 kcal morl ) for the MLH and ML 











MLH_1, (g), 5,5,5 MLH_lT (h), 5,5,8 
MLH_2, (j), 5,5,5 MLH-2' (k), 5,5,5,5 
Figure 4.4(2): Energy minimised Cu(II) complexes showing equatorial plane 
coordination by structure (g) an amine, a pyridine nitrogen donor and two amide 
nitrogen donor atoms, giving a 5,5,5 chelate ring sequence (91.21 kcal morl ), 
structure (h) two amine, a pyridine nitrogen donor and an amide nitrogen donor 
atom, giving a 5,5,8 chelate ring sequence (30.27 kcal mol-l ), structure (j) an amine, 
a pyridine nitrogen donor and two amide nitrogen donor atoms, giving a 5,5,5 
chelate ring sequence (85.36 kcal morl ) and structure (k) two amine, a pyridine 
nitrogen donor and two amide nitrogen donor atoms, giving a 5,5,5,5 chelate ring 












ML, (f), 5,5 MLH-l' (g), 5,5,5 
MLH_l' (h), 5,5,8 MLH_2t (j), 5,5,5 
Figure 4.4(3): Energy minimised Cu(II) complexes showing equatorial plane 
coordination by structure (f) an amine, a pyridine nitrogen donor and an amide 
nitrogen donor atoms, giving a 5,5 chelate ring sequence (62.94 kcal morl ), 
structure (g) an amine, a pyridine nitrogen donor and two amide nitrogen donor 
atoms, giving a 5,5,5 chelate ring sequence (120.26 kcal morl ), structure (h) two 
amines, a pyridine nitrogen donor and an amide nitrogen donor atoms, giving a 5,5,8 
chelate ring sequence (56.94 kcal morl ) and structure U) an amine, a pyridine 
nitrogen donor and two amide nitrogen donor atoms, giving a 5,5,5 chelate ring 












MLH_2, (k), 5,5,5,5 
Figure 4.4(3): Energy minimised Cu(II) complexes showing equatorial plane 
coordination by structure (k) two amine, a pyridine nitrogen donor and two amide 
nitrogen donor atoms, giving a 5,5,5,5 chelate ring sequence (102.95 kcal morl ) for 
the MLH-l and MLH_2 species of the Cu(II)-PrDM system. 
MLH, (a), 7,5 ML, (f), 5,5 
Figure 4.4(4): Energy minimised Cu(II) complexes showing equatorial plane 
coordination by structure (a) an amine, a pyridine nitrogen donor and a carbonyl 
oxygen donor atom, giving a 7,5 chelate ring sequence (85.49 kcal morl ) and 
structure (f) an amine, a pyridine nitrogen donor and an amide nitrogen donor atom, 
giving a 5,5 chelate ring sequence (61.51 kcal morl ) for the MLH and ML species of 











MLH_1, (g), 5,5,5 MLH_1, (h), 5,5,8 
MLH-2, (j), 5,5,5 MLH_2t (k), 5,5,5,5 
Figure 4.4(4): Energy minimised Cu(II) complexes showing equatorial plane 
coordination by structure (g) an amine, a pyridine nitrogen donor and two amide 
nitrogen donor atoms, giving a 5,5,5 chelate ring sequence (116.07 kcal morl ), 
structure (h) two amine, a pyridine nitrogen donor and an amide nitrogen donor 
atom, giving a 5,5,8 chelate ring sequence (58.59 kcal morl ), structure (j) an amine, 
a pyridine nitrogen donor and two amide nitrogen donor atoms, giving a 5,5,5 
chelate ring sequence (82.94 kcal morl ) and structure (k) two amine, a pyridine 
nitrogen donor and two amide nitrogen donor atoms, giving a 5,5,5,5 chelate ring 












Table 4.3: Internal energy (Einternal), bond (Ebond), angle (Eangle), torsion (Etorsion) and out-of-plane (Eoop) deformation energies (kcal marl) for 
the different chelate ring size sequences associated with each structure for the Cu(II)-PrDH, Cu(II)-PrDM and Cu(II)-PrDPr systems. 
(a) 
PrDH 7,5 
" .. Einternal 109.36 
I E bond 15.02 
I Eangle I 56.29 
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Table 4.3 shows the molecular mechanics calculations output data of the 
different deformation energies including the internal energy from the complex 
structures. The results show that the strain energy corresponding to a chelate 
ring size formed by coordination of nitrogen donor atoms to the metal ion is 
in the order 5,5,5,5 > 5,5,5 > 5,5 > 5,8,5 > 5,5,8. It is observed that the 
5,5,5,5 and 5,5,5 chelate ring systems are highly strained. In general, the 5,7 
or 5,8 chelate rings tend to have unfavourable larger chelate rings. However, 
the 5,8,5 and 5,5,8 chelate ring systems in this study seem to be stabilized as 
compared to the 5,5 chelate ring system due to the pre-organization of the 
ligand. The results also show that structures involving carbonyl oxygen donor 
atoms coordinated to the metal ion are relatively more strained. The rigidity 
of the pyridine mOiety seems to contribute to the strain energy when the 
carbonyl oxygen donor atom is coordinated to the metal ion. Therefore, the 
strain energy of these structures arises from both the sequence and the size 
of the rings formed around the metal ion upon different donor atom 
coordination. 
It is worth noting that molecular mechanics has been used in this study as a 
simple computational tool to provide more evidence in support of the 
potentiometric and spectroscopic (NMR, IR, UV-visible) studies. In all 
calculations, no account is taken for the electronic contribution, Jahn-Teller 
distortion of Cu(II), entropy effects, chelate effect of the ligand and solvent 
effect. 
4.4.5 Discussion - Proposed structures 
On the basis of the selected equilibria from the potentiometric data, the 
proposed structures for various species have been postulated and presented 
in Figure 4.4(1). The proposed MLH species for the ligands are given in Figure 
4.4(1) (a,b). The NMR study shows that the central pyridine nitrogen is 
coordinated at the beginning of complexation. Between the two structures, 











molecular mechanics calculations for the strain energy. This structure is 
formed by the Cu(II)-PrDH and Cu(II)-PrDPr systems. It is expected that as 
the pH increases, Cu(II) would induce ionization of the amide protons37,38 and 
there would also be a transition from Cu-O to Cu-N in the coordination 
arrangement. 39 The ML species is formed by the deprotonation of the f'lILH 
species. Several possible arrangements exist in forming this species as shown 
in Figure 4.4(1) (c,d,e,f). From the molecular mechanics calculations, 
structure (f) has the lowest strain energy, thus being favoured over the other 
three structures. Moreover, IR and NMR studies show that the deprotonation 
of the amide group begins at an early stage (low pH). The incorporation of an 
anchor (central pyridyl nitrogen) would also induce ionization of the amide 
proton by bringing the metal ion into close proximity. The rigidity of the 
pyridine moiety would also destabilize the other two structures upon 
coordination to the carbonyl oxygens. 
The possible structures for the MLH-l species are shown in 
Figure 4.4( 1) (g,h,i). Structure (i) is unlikely to be formed due to the 
coordination of the carbonyl oxygen to the metal ion. According to the 
molecular mechanics calculations, structure (h) is less strained as compared 
to (g). However, the amide coordination is likely, due to the close proximity of 
the metal ion enhanced by the coordination of the central pyridyl nitrogen. 
Brooker and co-workers4o reported similar structure for Cu(II) with dioxo 
pentadentate ligand analogue of the ligands in this study. The IR and I\IMR 
studies show that the amide nitrogens are involved in complexation. If 
structure (g) is formed, the MLH-2 species would result from the 
deprotonation of the terminal amino/pyridyl nitrogen group, structure 0). 
However, structure (i) would result in the formation of (k). The structure (k) 
is highly strained by 5,5,5,5 membered chelate rings. Although structure (I) 
has the lowest strain energy amongst the MLH-2 species, the NMR study 
shows that the pyridyl nitrogen is coordinated to the metal ion. The UV-visible 
study shows that the species formed are of tetragonal geometry. The UV-











all nitrogen donors coordinated to the metal ion. The coordination geometry 
of the MLH-2 species in both Cu(I1)-PrDH and Cu(I1)-PrDM systems is likely to 
be overall tetragonal with only a weak axial nitrogen donor for the fifth 
nitrogen. The proposed most likely structures formed for the Cu(II)-PrDH, 
Cu(II)-PrDM and CU(II)-PrDPr systems in solution are given in Figure 4.4(5), 
9ro - NR2=@ PrOPr eNH 0\1,. NH 
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MLH 
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Figure 4.4(5): Schematic representation of the most likely structures formed in 
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5. BIO-MODELLING AND ANIMAL EXPERIMENTS 
5.1 THE BLOOD PLASMA MODEL 
5.1.1 Introduction 
Of importance in this study is to produce a ligand (drug) that would be able 
to mobilize Cu(II) in blood plasma. In biological fluids, the greater percentage 
of metal ions is bound to proteins. Actually, only a small fraction of these are 
bound to low molecular weight (Lm.w) compounds, mainly amino acids. Free 
(hydrated) metal ions exist in biological fluids only at extremely low 
concentrationsl and these concentrations cannot play a significant role in 
physiological processes. 1 However, metals bound to I.m.w compounds playa 
major role in many biological and physiological processes like intestinal 
absorption, cell absorption and renal excretion. 1 The Lm.w complexes are 
believed to be involved (i) as intermediates when metal ions are inserted into 
or removed from certain metalloenzymes or carrier proteins, (ii) in the 
transfer of certain metal ions across membranes, (iii) in keeping essential 
metals in solution and (iv) in altering the potential of certain redox couples. 
Therefore, the knowledge of the equilibrium distribution of metal ions 
between Lm.w ligands is highly desirable.2,3,4 
Metal ions which are considered essential to human life include calcium, 
magnesium, manganese, iron, cobalt, copper and zinc.2,3 Of particular interest 
in this study are I.m.w. complexes of copper. In blood plasma, 90% of the 
copper is irreversibly bound to ceruloplasmin, 10 % is reversibly bound to 
serum albumen and a small amount <10/0 is distributed amongst I.m.w 
complexes, predominantly [Cu(histidate)(cystinate)].6 In patients with 
inflammatory disease, elevated levels of plasma copper are found and these 
levels return to normal upon remission. 7 It is thought that the I.m.w fraction 
of copper is responsible for anti-inflammatory activity, possibly by making the 











The total concentrations of lV1n(II), Fe(III), Cu(II), Zn(II) and Pb(II) in normal 
blood plasma are between 1 x 10-7 and 5 x 10-5 mol dm-3.2,4 The 
corresponding minute concentrations of the respective free ions are far below 
the limit of detection by any analytical technique. It is also very difficult to get 
information from large chemical systems because of their complexity. Because 
of these limitations computer models simulating the complex systems have 
been developed. 
Computer simulations of the metal-ligand equilibria in blood plasma have 
been performed using the general computer programs, COMICS and 
HALTAFALL.8 They were both limited in respect of the way they stored data 
and in respect of their equation solving algorithms. They could not, therefore, 
treat hundreds of components and tens of thousands of complexes which 
might reasonably be expected to form in a complicated mixture such as blood 
plasma.8 
For this reason, a specialized computer program was written in order to 
handle a large number of possible species. This was called ECCLES 
(Evaluation of Constituent Concentrations in Large Equilibrium Systems).2 
ECCLES solves the relevant mass balance equations and displays the resulting 
species distributions in an ordered way to enable changes in concentrations of 
the major complexes to be readily monitored. One of the major features of 
ECCLES is its preprocessor MIX which generates estimates of the equilibrium 
constants for the many mixed (ternary) complexes that might be important in 
the blood plasma.8 Most of these complexes are mixed, ternary complexes of 
histidine and another amino aCid.9,lo 
In order to understand the effect of the ligand (drug) on the equilibria 
present in this model, formation constants of the ligand and the species of 
interest determined in vitro, are incorporated into a database. This database, 











computer program to yield results pertaining to the influence of this drug on 
these equilibria. 
One of the limitations of this program is that protein equilibria are not 
included and therefore the concept of plasma mobilizing index (p.m.i) is used. 
It is defined as the ratio of the total concentration of I.m.w metal complex 
species in the presence of the drug to that in normal blood plasma. ll In 
simple terms, p.m.i is a measure of the ability of the administered ligand to 
move the metal ion from the protein bound fraction to the I.m.w fraction. It is 
based on the premise that the free concentration of the metal ion is buffered 
and hence held constant during any reasonable perturbation. 
S.1.2 Blood plasma simulations 
In investigating the copper specificity of the ligands of present study, the 
potentiometrically determined stability constants of Cu(U), Ni(U), Zn(U) and 
Ca(U) complexes were added to the updated ECCLES modeI12,13 of blood 
plasma so as to calculate the plasma mobilizing indices. The blood plasma 
model consists of data for 10 metal ions and more than 5 000 ligands. This 
enlarged database was then interrogated by ECCLES to yield p.m.i's as a 
function of concentration. In the calculation, the total ligand concentration 
was varied over the range 10-5 - 100 mol dm-3• The results are presented in 
Figure 5.1(a), (b) and (c). 
Figure 5.1(a) shows the Cu(U) p.m.i curves for PrDH and PrDPr as well as 
those of related ligands, TIDA, L3e, and PCUA. One important observation 
from this figure is the absence of Cu(U) p.m.i for PrDM. This ligand was 
observed to give a log p.m.i value of 0.01 at high concentration (1 mol dm-3). 
This indicates that PrDM has low mobilizing ability in blood plasma and thus 
cannot effectively increase the I.m.w Cu(U) fraction. Although the Cu(U) p.m.i 
curve for PrDH can be seen in the Figure 5.1(a)r this ligand also shows low 











systems. The reason for the low mobilizing ability of these two ligands is the 
stability of their complexes with Zn(II) and Ca(II). For example, in Figure 
S.l(b), a 10-1 concentration of PrDH causes three folds increase in I,m.w 
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Figure S.l(a): Logarithms of Cu(II) plasma mobilizing index as a function of 
logarithms of the ligand concentration for PrDH and PrDPr, and related ligands, 
TIDA, L3e, and PCUA. 
On the other hand PrDPr is 4 orders of magnitude better at mobilizing Cu(II) 
in vivo than PrDH. In comparison with related ligands, PrDPr is two to three 
orders of magnitude better at mobilizing Cu(II) in vivo than L3e (NS-donor, 
Figure 3.17) and PCUA (N4-donor, Figure 2.1) respectively. However, TIDA 
(N4-donor, Figure 3.17) is about six orders of magnitude better than PrDPr. 
The NS-donor, L3g was included in the model and it produced a log p.m.i 
value of 0.01 at 1 mol dm-3. 
Figure S.l(b) shows p.m.i curves for Cu(II), Ni(II), Zn(II) and Ca(II) with 
PrDH plotted against logarithms of the concentration of the ligand. The curves 
indicate that the mobilizing ability of PrDH in vivo is in the order Ca(II) > 
Zn(II) > Cu(II) ~ Ni(II). Therefore, Ca(II) and Zn(II) are good competitors of 
Cu(II) for PrDH in blood plasma. For the PrDPr system shown in Figure S.l(c), 











remarkably high mobilizing ability of this ligand is related to the stable 
complexes it forms with Cu(II). In addition, the predominant CuLH-2 species 
of this ligand is present at the physiological pH. At a total ligand concentration 
of 3.1 x 10-3 mol dm-3 for PrDPr, the p.m.i's for Zn(II) and Ca(II) p.m.i's are 
very low « 0.01). In spite of the higher concentrations of these in vivo 
competitors and the predominance of the MLH-2 and ML species for the two 
metal ions respectively, their weak binding strength with PrDPr make them 
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Figure S.l(b): Logarithms of Cu(II), Zn(II), Zn(II) and Ca(II) plasma mobilizing 
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Figure S.l(c): Logarithms of Cu(II), Zn(II), Zn(II) and Ca(II) plasma mobilizing 











5.2 SUPEROXIDE DISMUTASE MIMETIC ACTIVITY STUDIES 
5.2.1 Introduction 
The beneficial role of copper in minimizing inflammation has been attributed 
to its redox activity, particularly the ability of copper in such enzymes as 
superoxide dismutase (SOD) to remove the highly pro-inflammatory 
superoxide anion radical, 02'-.14,15 The superoxide anion radical is a highly 
reactive toxic species found in many biological systems. It is formed by the 
reduction of dioxygen, 02.14-19 Phagocytic cells appear to have specialized in 
such 02'- production due to a membrane-associated 02'- - producing NAD(P)H 
oxidase.1s Along with hydrogen peroxide (H202) and the hydroxyl radical 
COH)/ superoxide has been implicated in oxidative damage phenomena 
related to aging, inflammation and post-ischemic injury via reperfusion. 1S,17 
The 02'- radical has also been implicated in the promotion of arthritis due to 
its ability to degrade hyaluronic acid and bovine synovial fluid. 2o Moreover, 
O2'- released from activated neutrophils produces a chemotaxin by reacting 
with a component of blood plasma. 1s This has the effect of allowing one 
activated neutrophil to recruit others and thus to produce local inflammation. 
It also inactivates catalases, peroxidases, dihydroxy acid dehydrase and other 
enzymes. However, the cytochrome oxidase decreases H202 and 02 ~ in the 
cells by direct conversion of dioxygen in respiring cell to water whereas SODs, 
catalases and peroxidases utilize a variety of electron donors to reduce H202 
into water. 14,lS,18,21,22 
Of importance in this study is copper-zinc SOD which provides cellular 
defence against the oxidative stress by catalyzing 02'- disproportionation into 
less toxic dioxygen and hydrogen peroxide. The CuZnSOD is found in the 
cytosols of eukaryotic cells. 1s,17 During catalytiC process[ copper undergoes 
valence changes while zinc mainly plays a structural role. The Cu(II) and 











conduction, which might otherwise become rate-limiting. Upon reduction of 
the Cu(II) by O2*-, the Cu-imidazolate bond is broken and the imidazolate 
becomes protonated. Then, during reoxidation of the Cu(I) by the next O2'-, 
the Cu-imidazolate bond is re-established while the proton converts the 
reduced O2 ~ to H02'-, which leaves the active site and picks up a second 
proton to become H202. This process has been summarized as follows/S,16 
Cu(II) + 02-- H Cu(I) + 02 
Cu(I) + 02-- + 2H+ H Cu(II) + H20 2 




A number of Cu(II) complexes including those of polypeptides have been 
reported to exhibit SOD-mimic activity and thus are viewed as alternative 
human therapeutics to remove the prO-inflammatory superoxide anion radical 
in viVO. 14,23 In fact, low molecular weight Cu(II) complexes are capable of 
catalyzing the dismutation of the superoxide anion radical to dioxygen, water 
and/or hydrogen peroxide. 14,23 
5.2.2 Determination of Cu(II}-L SOD Mimetic Activity 
Accurate measurement of the ability of a given SOD mimic to catalyze the 
dismutation of superoxide is essential for establishing a correlation between 
pharmacological effect and SOD activity. Several methods, either direct or 
indirect are available for SOD activity determination. UV-visible is the most 
widely used method. It is an indirect method which is based on two elements, 
a superoxide generator usually a xanthine-xanthine oxidase system and a 
detector, nitroblue tetrazolium (NBT).14,24 In the absence of an SOD-mimetic 
agent (control experiment), the radicals react with the detector whereas in 
the presence of SOD-mimetic agent (inhibition experiment), this agent 











The SOD activity is measured by the degree of inhibition of the conversion 
process of NBT to form diformazan using UV-visible spectrophotometry at 560 
nm over a period of time. The absorbance versus time curves corresponding 
to a control and particular concentrations of an SOD mimic (Cu(II)-L complex) 
are generated and slopes of these curves computed. The %Inhibition of the 
reduction of NBT to blue diformazan is calculated using the following 
equation; 
01 1 h'b't' [(Sees SieJxl00] 10 n I I Ion = ~="'----!:=..:---:;;;. 
Sees 
(5.4) 
where Sees and Sies are slopes of the control and inhibition experimental 
solutions respectively. Values of %Inhibition against varying drug 
concentration are plotted. The inhibitory concentration (IC50) defined as 
concentration of the drug required to reduce diformazon by 50% is read off 
from these plots. 
These experiments are carried out in the presence of excess disodium salt of 
EDTA as compared to other components. This condition stimulates the 
competitive binding of endogenously available I,m.w Iigands24,25 and also 
enable complexation of small amounts of the metal ions such as Fe(III) that 
may be present in NBT and/or xanthine, which are known to catalyze the 
dismutation of superoxide anion as wel1,24 It should be noted that Cu(II)-
EDTA complexes are inactive as SOD mimics. 
5.2.3 Experimental 
The superoxide dismutase mimetic activity of Cu(II)-L (L= PrDH, PrDM, PrDPr 
and PCUA) complexes were determined using NBT assay.14,24,25 Standard 
solutions of (i) 0.0004 M xanthine, (ii) 0.0001 M EDTA, (iii) 0.0001 g/cm3 of 
catalase, (iv) 0.018 units/cm3 xanthine oxidase and (v) 0.001 M solutions of 











In a 4 cm3 cuvette, 0.6 cm3 xanthine, 0.2 cm3 EDTA, 0.2 cm3 NBT, 0.1 cm3 
catalase and 2.9 cm3 of phosphate buffer were added and this constituted a 
blank solution. In a control experiment, in addition to these compounds, 0.4 
cm3 xanthine oxidase and 2.5 cm3 instead of 2.9 cm3 phosphate buffer 
solution were added while in a test solution varying amounts of Cu(II)-L 
complex solutions were added prior to the addition of xanthine oxidase. The 
concentrations of Cu(II)-L SOD mimics ranged from 2.5 x 10-6 mol dm-3 to 
4.5 x 10-4 mol dm-3• 
The absorbance readings at 560 nm were obtained at 30 seconds intervals for 
a total period of 10 minutes for the control and experimental SOD solutions. 
For each set of readings corresponding to a control and a particular 
concentration of SOD mimic (Cu(II)-L complex), the absorbance was plotted 
against time and the slopes of the resulting plots were computed. The 
%inhibition of the reduction of NBT to formazan was calculated using 
equation 5.4 and ICso values Similarly determined from plots of %inhibition 
versus concentration of the Cu(II)-L complex. 
5.2.4 Results and discussion 
5.2.4.1 Cu{U)-L Systems 
Figure 5.2 (a), (b), (c) and (d) show the percentage inhibition as a function of 
the concentration of the Cu(II) complexes for the ligand systems, PrDH, 
PrDM, PrDPr and PCUA respectively. The concentration of the drug required 
to reduce diformazan formation by 50%, also known as ICso can be easily 
read off from these graphs. 
IC50 values of 199, 31.3, 275 and 233 ~lmol dm-3 for the Cu(II)-PrDH, Cu(II)-
PrDM, Cu(II)-PrDPr and Cu(II)-PCUA complexes have been obtained as 
shown in Figure 5.2 (a), (b), (c) and (d) respectively. These values are 











MLH-tlMLH-2 species for PrDPr and PCUA systems respectively. The IC50 
values of the native CuZnSOD (= 0.011 )lM)26, CU2Zn2S0D (= 0.006 )lM)14 
and bovine erythrocyte SOD (= 0.04 )lM?7 have been reported. The IC50 
values recorded in this work for the studied Cu(ll) complexes are much 
higher than these values. Therefore, Cu(ll) complexes of the present study 
have low SOD activities as compared to the native enzyme. The IC50 values of 
some Cu(ll) complexes of amino acids such as tyrosine (= 45 )lM) and lysine 
(= 86 )lM) and, non-steroidal anti-inflammatory drugs (NSAIDs) such as 
salicylates (= 2-28 )lM) have been reported. 28,29 These values are reasonably 
or rather relatively close to those obtained in this study. Moreover, 
Mkhonta-Gama3o reported IC50 values for the related dioxo N5-donor ligands 
(L3C_L3f, Figure 3.17) in the range 131 - 195 )l1V1 whereas l\lomkok031 reported 
a value of 11.7 )lM for the dioxo N5-donor ligand (L3g, Figure 3.17). 
An important observation in the results of the present study is the fact that 
the IC50 values correlate with the corresponding p.m.i values. The Cu(ll)-L 
system with low log p.m.i value or rather low mobilizing ability in blood 
plasma is observed to possess relatively high SOD mimetic activity. In this 
case it is the Cu(Il)-PrDIV1 system which shows relatively high SOD mimetic 
activity whereas the Cu(Il)-PrDPr system which showed relatively high 
mobilizing ability in blood plasma shows low SOD mimetic activity. The low 
IC50 value exhibited by the Cu(Il)-PrDM system can be interpreted in terms of 
the possible replacement of coordinated water molecule by the superoxide 
anion radical. Moreover, the presence of the protonated ligand's sites of the 
MLH-l species should also contribute to the dismutation of the superoxide 
anion radical through hydrogen bonding. On the other hand, the high IC50 
value may be due to the unavailability of the binding sites for the superoxide 
anion radical to coordinate to the metal ion. Important requirements for SOD-
like activity are a medium donor power and the flexibility of the ligands, in 
order to facilitate the reduction and the accommodation of Cu(I), which is 











geometry of the native SOD enzyme is distorted square-pyramidal for Cu(II) 
and distorted tetrahedral for Zn(II). 
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Figure 5.2 %Inhibition as a function of concentration of MLH-2 and MLH_l species for 











5.3 OCTANOL/WATER PARTITION COEFFICIENTS 
5.3.1 Introduction 
One important aspect upon which biological activity depends is the ability of 
the drug to reach the target area of action. In the human body, drugs have to 
traverse a number of body tissues before they can impart their therapeutic 
effect. Transport across the skin and bio-membranes in general is a process 
of limited diffusion governed by the drugs' chemical and physical properties 
such as lipophilicity and protein binding.32,33 
Partition coefficients measurements can be used as reference parameter for 
hydrophobicity in biochemical and pharmacological systems. The measure of 
hydrophobicity can be expressed as the logarithm of the partition coefficient 
between l-octanol and an aqueous phase.38 For Cu(II)-complex as a drug, 
this may be given as; 
- ([cu2+ ]org J 
LogPoct!water - Log [Cu2+]aQ (5.5) 
where [CU2+]org and [Cu2+Jaq are the concentrations of Cu(ll) in the organic 
and aqueous phases respectively. 
An investigation of a biphasic system at varying pH values interestingly shows 
the role that speCiation plays in the determination of the partition coefficients. 
The amount of Cu(ll) transferred from aqueous solution to organic layer 
changes with pH because speciation changes with pH and the different 
species have different partition coefficients. Moreover, the change in charge 
in successive complex formation is accompanied by a change in the solubility 
of the solutes (species) in the two phases.36 
Partition coefficients are usually employed as criteria in quantitative structure-











used in the estimation of bioaccumulation in animals and plants, and in the 
prediction of toxicity and drug absorption.38 
5.3.2 Experimental 
The commonly used experimental (traditional) method for the determination 
of partition coefficients (logPoct/aq) is the shake-flask method, which is adopted 
as the standard OECD (Organisation for Economic Cooperation and 
Development) method.37 However, for compounds having higher 
hydrophobicity, this method cannot be used because of the formation of 
odanol emulsions in water.38 
In this study partition coefficients were determined using the shake-flask.39,40 
100 cm3 of Cu(ll) (0.001 mol dm-3) - L (0.002 mol dm-3 ) solutions were 
prepared. Into fifteen 20 cm3 glass vials,S cm3 portions of the metal-ligand 
solutions were pipetted. The first vial was left at pH 3.0 while the rest of the 
vials were adjusted in 0.5 pH increments apart using 0.1 mol dm-3 of NaOH. 
These solutions were then spiked with 64CuCI2 solution of activity 5 - 7.5 mCi. 
To each vial containing the spiked metal-ligand solution, 5 cm3 portions of 
water saturated l-octanol were added. These were then stoppered and 
shaken for 5 minutes, swirled to collect droplets from sides of the vials and 
set aside to allow the two phases to separate at a constant temperature of 
25 0c. 1 cm3 of each phase was pipetted into radioactive counting vials using 
a microlitre pipette and activity of each phase counted for 5 minutes in a 
Minaxi Auto gamma counter (5000 Series-Packard) using a window set at 











5.3.3 Results and discussion 
5.3.3.1 Cu{I1)-L systems 
Figure 5.3(a), (b), (c) and (d) show the partition coefficients (logPoct/aq) of 
Cu(II)-PrDH, Cu(II)-PrDM, Cu(II)-PrDPr and Cu(II)-PCUA systems as a 
function of pH respectively. These logPoct/aq values were determined at 25 °c 
and an ionic strength of 0.15 mol dm-3 (CnNa+. 
Observed in Figure 5.3(a), (b), (c) and (d) is the fact that all logPoct/aq values 
are negative. The negative values of logPoct/aq indicate that these complexes 
are largely hydrophilic. The logPoct/aq values -2.35, -2.11, -0.58 and -1.65 for 
the Cu(II)-PrDH, Cu(II)-PrDM, Cu(II)-PrDPr and Cu(II)-PCUA systems have 
been obtained at physiological pH (7.4) respectively. The low values in the 
acidic pH range for the complex species is indicative of the presence of 
hydrated [CU(OH2)6f+ species. This would be highly expected for PrDH and 
PrDM systems for which Cu(II) complexation commences at pH>4. 
The speciation graphs show that Cu(II) complexation commences at 
approximately pH 4.5 for PrDH (Figure 3.5(c» and pH 5 for PrDM 
(Figure 3.8(c» systems and therefore, high concentrations of hydrated 
[CU(OH2)6f+ species are expected below these pH values. There is an 
increase in logPoctjaq values as pH increases due to various species formed 
from Cu(II) with PrDH and PrDM (Figure 5.3(a) and (b». The logPoct/aq value 
of -2.23 at pH 6.5 is associated to the ML species for the PrDM system 
whereas the value of -2.51 at pH 6.0 is associated with the MLH/ML species 
for PrDH system. These species are tri/di-positively charged, a factor that 
could enhance their association with the aqueous solution. At physiological 
pH, rvlLH-l is the predominant species for both systems and it is observed that 
approximately 0.43% of the Cu(II)-PrDH and 0.83% of the Cu(II)-PrDM 
complexes are extracted into the organic phase of the octanol-water mixture 











logPoct/aq values as pH is increased from 8-10 due to the formation of MLH-2 
with maximum logPoct/aq values of -1.72 and -0.83 for the PrDH and PrDM 
systems respectively. Formation of the neutral MLH-2 species enhances 
extraction into the organic phase. The relatively hydrophilic nature of these 
two ligands in addition to the charge distributions, explains the complexes' 
preference for the aqueous layer resulting in negative values of logPoct/ag. 
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Figure 5.3 Logarithms of octanol-water partition coefficients as functions of pH for 












For the CU(II)-PrDPr system the logPoct/aq values are higher than those of the 
other three systems in this study as shown in Figure 5.3(c). For this system 
Cu(II) complexation begins at low pH (= 2.2, Figure 3.12(c» by the formation 
of the MLH species which predominates at pH 3.2. Therefore, logPoct/aq of 
-2.21 is assigned to this species. On the other hand, complexation of Cu(II) 
with PCUA begins at pH 2.5 with formation of the MLH species predominating 
at pH 5.1, giving a logPoct/aq value of -2.44 (Figure 5.3(d». Unlike the PCUA 
system for which the ML species predominates at pH 6.5 (logPoct/aq = -1.82), 
the ML species of the CU(II)-PrDPr system overlaps or rather coexists with 
both MLH and MLH-l species. However, rvILH-1 species of the PrDPr system 
predominates at pH 4.8 thus being assigned to logPoct/aq value of -0.98. The 
positively charged species would be expected to result in negative logPoct/aq 
values due to the ability of water to stabilize charges. At physiological pH the 
MLH-2 and MLH-l are the predominant species for PrDPr and PCUA 
respectively and it is observed that 19% of Cu(II)-PrDPr and 2.9% of Cu(II)-
PCUA complexes are extracted into the organic phase of the octanol-water 
mixture. Although these complexes are relatively hydrophilic by virtue of 
having negative logPoct/aq values, they are more lipophilic than PrDH and PrDM 
systems. The amount of the CU(II)-PrDPr complex (19% ) extracted into the 
organic phase of the octanol-water mixture is reasonably good for transport 
across bio-membranes. The relatively high amount of this complex extracted 
into the organic phase is due to the presence of the bulky groups and this 
suggests the essential role of such groups in percutaneous drug 
administration. It was therefore, expected that the incorporation of the benzyl 
group would enhance lipophilicity of the complex. 
Jackson and coworkers41 reported logPoct/aq values for the related Cu(II) 
complexes of dioxo N5-donor ligands in the range -3.70 to -6.63 for the MLH, 
ML, MLH-l and MLH-2 species. Nomkoko and coworkers42 also reported 
logPoct/aq value of -1.25 at physiological pH (7.4) for the related dioxo 











inflammatory drugs have been reported.4o Therefore, for a drug (complex) to 
be reasonably lipophilic the logPoct/aq value must be at least 0.618. The value 
of logPoct/aq = -0.58 for the Cu(II)-PrDPr system shows that this complex is 
relatively lipophilic. Mathias and coworkers43t44 have reported positive logPoct/aq 
values for the positively charged complexes thus indicating that the 
electrostatic interactions are not the sole factor governing octanol-water 
partition.45 Rothwell and coworkers46 have recently reported the octanol-
water partition coefficients of Quercetin and related flavonoids in the range 
-1.11 to 3.22. The consumption of flavonoids has been associated with 
protection against coronary heart disease and cancer. Several workers47-49 
studied 64Cu-labeled complexes of logPoct/aq values in the range -1.60 to -3.02 
for potential use as attaching copper radionuclides to biological molecules for 
diagnostic imaging and targeted radiotherapy. Therefore, the results obtained 
in this study are encouraging considering that they fall in the above range 
and also that the CU(II)-PrDPr complex is reasonably lipophilic at physiological 
pH (7.4). 
In general, neutral species (complexes) take part in the partition equilibrium 
between the aqueous and organic phases while charged species remain in the 
aqueous phase. The contributing factors to the hydrophilicity of the present 
complexes are; a) the presence of coordinated water molecules, b) hydrogen 
bonding between charged groups in these species and the solvent molecules, 
c) the overall charge of the MLH, ML, MLH-l complex and d) hydrogen 












5.4 BIO-DISTRIBUTION STUDIES 
5.4.1 Introduction 
As an essential element, copper plays an important role in all living organisms 
including humans.so Biologically active oxidation states of copper, I, II and III, 
are found in copper complexes that act to transport copper to body sites 
where it is required.so Free copper may be toxic and therefore, copper exists 
mostly in complexed forms, bound to macromolecules and low molecular 
weight ligands in body fluids.51 Dietary copper is readily absorbed in the 
stomach and small intestine, from which it is transported to the liver by the 
blood as a serum albumin complex. It is in the liver that copper is processed 
and stored as a metallothionein complex or converted into ceruloplasmin 
which is released into the blood to meet normal metabolic needs. 52~54 
The body of a healthy, 70 kilogram, human adult contains approximately 110 
milligrams of copper, much of it in the liver (10 mg), brain (8.8 mg), blood (6 
mg), skeleton (including the bone marrow; 46 mg), and muscle (26 mg).29/55 
The daily intake of copper in the human body is approximately 1.5 - 3 mg.29 
In humans copper absorption varies inversely with dietary copper intakes6 and 
absorption occurs primarily in the small intestines7 after digestion of food in 
the stomach and duodenum. 58 Once absorbed, approximately 70 - 80% of 
plasma copper is in non-exchangeable forms, bound to ceruloplasmin. The 
remainder is bound to albumin, transcuprein, metallothionein and low 
molecular weight complexes as the exchangeable copper fraction in blood.58/59 
A summary of the nutritional biochemistry and metabolism of copper for adult 
humans presented by Linder and Hazegh-Azams8 is shown in Figure 5.4(a). 
Values for copper indicate average daily amounts of copper ingested, 
absorbed and secreted via various routes. Concentrations of copper in fluids 
are also shown as well as total amounts of copper in various tissues. 
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Figure 5.4{a): A summary of the nutritional biochemistry and metabolism of copper 
for adult humans.58 
It was observed after intraperitoneal injection of tracer amounts of 67CU in 
mice that all of the copper rapidly left the blood and entered the liver and 
kidney before re-emerging in the plasma.55 The uptake of the administered 
isotope by other tissues and organs such as heart and brain appeared to take 
place mainly during the re-emerging of copper in the plasma. The present 
study investigates copper bio-distribution in mice using 64Cu(II) as a 
radiotracer for the copper chelating agents. This allows the determination of 
the changed bioavailability and efficacy of these agents in transporting Cu(II) 
through the body to possible sites of inflammation as well as determining the 











with potentiometric (section 3.5), blood plasma model (section 5.1.2) and 
octanol-water partition coefficients (section 5.3.3) results. 
5.4.2 Experimental 
Sio-distribution studies on mice were approved by the Research Animals 
Ethics Committee of the University of Cape Town (permission number 
005/039). The authority to possess and use the radioactive nuclide 64Cu(II) 
(half-life = 12.7 hours) was granted by the University of Cape Town's 
radiation protection and health safety committee in conjunction with the 
Department of Health (authority number 33/01/0327). The procedures for 
carrying out experiments were done in compliance with the guidelines set by 
the University of Cape Town Research Animals Ethics Committee. 
The experimental approach adopted for these animal experiments was similar 
to the approach of Jackson and co-workers6o and, other workers48,49 in the 
field of nuclear mediCine. Solutions of Cu(II)(O.OOl mol dm-3) - L(0.003 mol 
dm-3) complexes of PrDH, PrDM, PrDPr and PCUA were prepared in sterile 
saline solution at pH 7.40. These prepared complex solutions (20 cm3) were 
spiked with 10-14 mCi 64CuCb(aq) (radiochemical purity> 98 %) 
A total of 48 female Salb/c mice of age 7-8 weeks weighing 19-23 grams 
were used in these experiments. The mice were housed in groups of three (3) 
mice per cage and were given food and water ad libitum during the 
investigation period. These groups of three mice were injected intravenously 
with 0.2 cm3, [64Cu]Cu(II)-L solution (containing 6.5 ~g Cu), of 5 !lCi activity 
via the tail vein. Another group of mice was injected with [64Cu]CuCb as a 
control experiment. The mice were kept individually in polycarbonate cages 
containing paper towelling for urine absorption. 
At 1, 6 and 24 hour post-injection time pOints, groups of mice (three at a 











from the heart. Various samples (liver, muscle, tail, heart, lung, kidney, 
spleen, head, intestines, and carcass) were removed, rinsed with NaCi (0.9 
%), dried and then weighed. The urine impregnated towelling was extracted 
with 100 cm3 of 10 % vjv HCI. The radioactivity in these samples as well as a 
10 cm3 aliqouts of the urine extract were counted using a Minaxi Autogamma 
5000 Series y counter, with the window set at 340-540 KeV. Control samples 
were counted alongside with the experimental samples. All readings were 
corrected for background noise by subtracting the activity of an empty sample 
bottle and also adjusted to activity at time zero according to the half-life of 
64Cu(II) using the exponential decay law given in equation 5.6. 
N = No e -IJ (5.6) 
where t is the time elapsed, A is the decay constant, N is the amount of 
activity after time t and No is the amount of activity at time t = O. The 
percentage injected dose per organ (%dosejorgan) and percentage injected 
per gram (%dosejg) were calculated from the corrected activity counts. 
Although low activity 64Cu(II) (tl/2 = 12.7) of 10 - 14 mCi was used in these 
experiments, precautionary measures were taken against possible exposure 
to the high penetrating abilities of high energy pOSitrons and gamma 
radiation. During these experiments! disposable gowns, gloves and radiation 
badges were worn. The preparation of [64Cu]Cu(II)-L complexes as well as 
injection of mice were performed behind lead brick walls. The aqueous 
solution of the radiolabeled [64Cu]Cu(II) complexes and [64Cu]CuCh were kept 
in closed containers under refrigeration. After all experiments, the materials 
including syringes, needles, disposables, the sacrificed animals and their 
respective excised organs were initially kept in a refrigerator for at least four 
weeks. This allowed the radioactivity to decay below safe levels before 











5.4.3 Results and discussion 
Based on the aforementioned in vitro results, it was deemed necessary to 
perform bio-distribution experiments. Since the body is a dynamic system, the 
biodistribution was measured as a function of time. The results given in 
Table 5.1 show %dose per organ and %dose per gram for [64Cu]Cu(II)-PrDH, 
[64Cu]Cu(II)-PrDM, [64Cu]Cu(II)-PrDPr and [64Cu]Cu(II)-PCUA as well as 
[
64CU]CuCb (control) at 1 hour time point. High activity in the carcass resulted 
in further excision of other organs but now at 6 and 24 hour post-injection. 
The excision of other organs was done in order to investigate the localization 
of this activity. The results are given in Table 5.2 and Table 5.3 including 
those of control experiments ([64Cu]CuCb). 
The bio-distribution results for the control, [64Cu]CuCb, show that there is 
rapid clearance from the blood with less than 1 %dose remaining 1 hour 
post-injection. The clearance is due to the high uptake by the liver with 61.57 
%dose after 1 hour and 63.69 %dose after 6 hours found in this organ. The 
activity dropped to 11.32 %dose 24 hour post-injection due to excretion 
through urine. The carcass, which is left after removing head and liver, 
recorded a high activity uptake of 31.51 %dose after 1 hour. After further 
excision of organs at time point 6 and 24 hours, the activity in carcass 
increased from 7.85 %dose 6 hour post-injection to 11.35 %dose after 24 
hours. Like the liver and carcass, intestines and kidney show increase in 
[64Cu]Cu(II) activity as shown in Table 5.1, thus suggesting that excretion is 
via hepatobiliary and renal routes. These results are in good agreement with 
those reported by Nomkoko and co-workers6o for [64Cu]CuCl2• The 
biodistribution pattern of the control experiments follows that of the normal 
metabolic pathway of copper reported by Linder and co-workers. 55 
The bio-distribution for the [64Cu]Cu(II) complexes of PrDH, PrDM, PrDPr and 
PCUA at 1 hour post injection is generally similar to those of the control. High 











control as shown in Table 1. This indicates that clearance from the blood 
system is slower for these complexes than for the control. However, the 
uptake by the liver (58.18 - 63.89 %dose) is approximately the same as that 
of the control (61.57 %dose). Like the control, [64Cu]Cu(II) complexes show 
high activity in the carcass after 1 hour with activity of 34.02, 36.04, 31.32 
and 29.16 %dose for PrDH, PrDM, PrDPr and PCUA systems respectively. 
Table 5.1: Sio-distribution of [64Cu]Cu(II) in mice for various ligands 1 hour post-
injection (%dose per organ and %dose per gram, mean ± std.dev' f n=3). 
[MCu]Cu(lI) complex, % dose per organ 
t=~-'-'l' I % dose per grar I, cu' C,'2 -l 
PrDH , PrDM i PrDPr I PCUA ~ r--------+------------------r----------l-----+-i---
Blood II 61 + 0 15 '1 39 + 0 20 12 89 + 056 11 38 + 0 39 i 080 + 0 08 ~ - - -
I 0:63 ~ 0:07 I , 1.3 1 ± 0.07 11.04±0.18 ,2.37±0.38 : I.J8±0.25 
~arcass 134.02 ± 4.68 ' -r 1 29.16 ± 2.87 i i 36.04 ± 9.95 131.32±3.78 131.51 ± 7.29 
I i 2.23 ± 0.35 2.14±0.71 2.02 ± 0.10 1.84 ± 0.21 2.00 ± 0.43 
I I I 
! 3.63 ± 0.35 ! Head ! 2.05 ± 0.02 I 3.20 ± 0.54 ' 3.42 ± O. J 0 2.54 ± 0.17 
I 
I 0.69 ± 0.06 i 1.06 ± 0.18 I 1.30 ± 0.11 : 1.09 ± 0.06 0.78 ± 0.01 
I, ! I -I Liver 1 6o.03 ±5.18 158.18±6.~~ I ~~.)3±2.69 • 63.89±2.25 61.57±6.91 
. 5737 ± 9.66 i 50.67 ± 2.¥.~-"~~7.65 _±_S_.3_8-+-_S2_.9_4_±_6_._18---, 











Table 5.2: Bio-distribution of [64Cu]Cu(II) complexes of PrDH, PrDM, PrDPr and PCUA (%dose per organ, mean ± std.dev., n=3) 
r64Cu]Cu(II)-PrDPr ("Cu(Cu(Il)-PCUA I (64Cu1CuCh 
24hr 6 hr 24hr 6 hr 24hr 6 hr 24hr 6 hr 24hr 
-- ,~~ r 
i 
1.02 0,13 0,83 0.05 2.24 ± 0.22 1.22 ± 2,08 ± 0.20 1.07 ± 0.17 1.86 0.14 0.80 ± 0.23 0.86 ± 0,24 
Carcass 8,10±1.39 7.43 ± 0.79 18,81 ± 3.52 7,08 ± 1.54 12.02 ± 0.29 6.94 ± 0,79 13.25 2,87 7,85± 1.87 11.35 1.77 
Head 1.94 0,08 4.41 ± 1.21 1.99 ± 0.20 4.72 ± 0,31 1.61 0.10 3.40 0,11 2.00 J 0.26 3,72:+: 0.21 1.94 ± 0,04 i 7.56 2.74 
Heart 0,28 (1.04 0.60 0.18 0.20 ,f, 0.03 0,55tO,14 0.21 J 0.02 0.46 0,05 0,28 0.04 0.44 0.04 0.19 0.02 0.21 ± 0.07 
Intestines 14,551 1.74 23.51 4.00 19.66 1.23 26.03 3.56 12.23 ± 0.99 30.25±4.18 16,80 ± 4.97 25.34 ± 5.61 22,17 ± 2,87 11.61 ± 6.94 
1.2·-1 i. 0,16 2.75 ± 0.62 1.15±0.08 2,72 ± 0.28 2,21 0.90 :UI ±0,34 1.15 ± 
7(),70 J 0,81 40.25 J 5, II 66,99 ± 1.31 38,98:! 6.99 64.31 2.89 35.56 9.26 67,89 5.42 33.57 ± 7,56 163,69 ± 5,06 III 
10.45±0,14 0.29 0,25 1.34 0.59 0,54 0.21 1.3() 0,14 1.00 ± 0.03 0.61 ± 0.07 0.96 
Muscle 
0.05 ± 001 0.09 ± 0.01 0.05:+: 0.02 0.14 0.06 0,06 ± 0.03 0.12±0,03 0.07 ± 0,01 0.15 
Spleen 
0.17 0.06 0.54 ± 0.23 0.23 ± 0.01 0.68 ± 0.18 10.14±003 0.30 0,13 0.28 ± 0.05 0.44 ± 
Urine 



















6 hr 24hr 
0.76 0.10 i 2.12±0.54 
0.66 ± 0.09 I 1.24 ± 0.21 
0.66 0.04 .46 0.35 
1.84 OAO 5.62 ± OA6 
;93 ± 0&0 8.27 0.&9 
3.03 ± 0.33 8.75 ± 0.62 
54.59 8.15 37.77 5.18 








0.63 ± 0.05 
0.65 ± 0.(J4 
.70 ± 0.22 
7.24 ± () 16 
3,32±0.19 
66.54 9.31 
3.22 ± 0.72 
6 hr 
I 
AO ± 0.17 I 0.60 ± 0.09 
.44 ± 0 14 
3.99 ± 0.26 
8.79 ± 1.00 
7.61 ± 0.59 
31.00 ± 6.13 
4.79 ± 0.85 
0.55 0.05 
1.80±0.15 





1.62 ± 0.27 
1.11 0.17 
1.11 .1 0.11 
3.56 i 0.74 
9.1& 2.13 
6.16 ± OA4 
30.48 ± 9.36 
6.23 0.45 
0.23 ± OAO I 0.44 ± 0.04 1.02 0.14 10.43 
± 0.31 5.22 ± 0.90 I 2.02 ± 
6 hr 24hr 6 hr 
0.87 0.10 IA9 ± 0.25 
0.61 0.05 1.16 ± 0.35 0.63 ± 0.17 
0.63 ± 0.08 1.13 :t 0.17 0.59 ± 0.02 
1.78 0.19 3.55 0.38 .56 ± 0.15 
5.84 ± 2.00 909 ± 4.09 8.14 1.12 
3.18±0.17 S.10±0.20 3.09 ±: 0.41 
56.36 ± 1.65 30.69 ± 7.56 56.20 OA5 
3.33 ± OAI 5.74±O.81 1.85 0.25 
± 0.10 I 0.90 
0.13 13.86± 
0.71 ±0.22 
0.95 ± 0.20 
2.60 ± 1.09 
l. 73 ± 0.43 
3.95 i 1.86 
3.03 ± 1.03 
11.32 0.64 


























Figure S.4(b): %dose per gram for • [64Cu]Cu(II)-PrDH, • [64Cu]Cu(II)-PrDM, 
[




















Figure S.4(c): %dose per gram for • [64Cu]Cu(II)-PrDH, • [64Cu]Cu(II)-PrDM, 
[































Figure S.4(d): %dose per sample for • [64Cu]Cu(II)-PrDH, • [64Cu]Cu(II)-PrDM, 
[

















Figure S.4(e): %dose per gram for • [64Cu]Cu(II)-PrDH, • [64Cu]Cu(II)-PrDM, 
[












At 6 and 24 hours post-injection redistribution of the [64Cu]Cu(II) complexes' 
activity occurs resulting in activity accumulation in the major organs as shown 
in Table 5.2 and 5.3. The results show that there is slow clearance from the 
blood after 24 hours for all four complex systems. This is clearly seen in 
Figure 5.4(b) for which the %dose per gram in the blood for the [64Cu]Cu(II) 
complexes is more than twice that of the control 24 hour post-injection. The 
liver shows high activity after 6 hours before activity slowly clears after 24 
hours. This is demonstrated in Figure 5.4(c) which shows %dose per gram in 
the liver for [64Cu]Cu(II) complexes including the control. The activity 
retention in the liver is in the range 33 - 40 %dose for these complexes 24 
hour post-injection whereas that of the control is about 11 %dose. The 
clearance from the liver results in accumulation in other organs as shown in 
Table 5.2. The high activity uptake of these complexes in the intestines 
suggests excretion into the intestine via the biliary route. The activity uptake 
in the intestine is in the range 23 - 30 %dose 24 hour post-injection as 
compared to 12 - 19 %dose 6 hour post-injection. The kidney shows activity 
after 6 hours which is increased 24 hour post-injection. This suggests possible 
excretion of these complexes via the renal route. However, rapid clearance 
via the renal route is observed for the control experiments as shown in Figure 
5.4(d) which shows %dose per sample in the urine for [64Cu]Cu(II) 
complexes. Of interest in these results is the fact that [64Cu]Cu(II)-PrDH, 
[64Cu]Cu(II)-PrDM, [64Cu]Cu(II)-PrDPr and [64Cu]Cu(II)-PCUA complexes 
are retained in the body as compared to the control ([64Cu]CuCI2) which is 
rapidly excreted via the hepatobiliary and renal routes. The activity retention 
in the body for these systems is about 50 %dose compared to 20 %dose for 
the control. 
There is also activity in other organs such as head, heart, lung, muscle and 
spleen as well as carcass. The relatively high accumulation of these 
complexes in these organs suggests that these complexes are more lipophilic 











pyridyl groups would enhance the lipophilicity of these complexes in vivo. 
Moreover, mono-positively charged and neutral species are formed at this pH 
thus increasing the uptake by tissues. Although, it was earlier observed from 
octanol-water partition and blood plasma model results that the PrOPr system 
is more lipophilic than PrOH, PrOM and PCUA, the results show that the 
[
64Cu]Cu(II) complexes of PrOH, PrOM, PrOPr and PCUA have more or less 
the same retention for these complexes in vivo. Therefore, it is important to 
compare bio-modelling (computer simulations) results with the experimental. 
In contrast to earlier observations, under the same conditions, by Jackson 
and co-workers41 for [64Cu]Cu(II) complexes of polyamino ligands, the 
presently investigated complexes have been found to be retained significantly 
by most of the organs. The aforementioned polyamino systems were 
observed to be rapidly excreted, unchanged via the renal route because they 
were too hydrophilic and stable such that the complex was excreted intact in 
the urine. Nomkoko and co-workers42,60,61 also studied poly(amine)amide 
ligands which showed that some of their systems were reasonably retained in 
the body under the same conditions. One of the noticeable features in their 
study and the present study is the fact that these systems have initial rapid 
and high uptake by the liver. The high uptake is to be expected in view of the 
fact that copper storing and metabolism occur in this organ. It has been 
suggested that the high uptake of [64Cu]Cu(II) by the liver is due to 
transchelation of the radioisotope by albumin and histidine, and these in vivo 
proteins and Lm.w ligands bind Cu(II) strongly.45 
Several studies have been performed by researchers using 64Cu-labeled 
species for different purposes. Anderson and co-workers45,62 have 
investigated thermodynamically and kinetically stable macrocyclic complexes 
with different formal charges as biofunctional chelators. All the complexes 
were observed to be rapidly cleared from circulation and positively charged 
complexes had higher liver uptake and slow clearance. The bio-distributions 











backbone and the formal charge on the complex thus suggesting that there 
are potentially many factors that control clearance and also that charge plays 
an important role. Further investigations on macrocyclic ligands as 
biofunctional chelators were carried out for attaching copper radionuclides to 
biological molecules for diagnostic imaging and target of radiotherapy.47,48 It 
was observed that positively charged 64CU complexes of the studied ligands 
exhibited rapid uptake in the liver and kidneys with slow clearance, whereas 
the negatively charged and neutral complexes cleared rapidly from all tissues. 
Packard and co-workers also reported Similar renal elimination for negatively 
charged 64Cu-labeled complexes.49 
In summary, the presently studied ligands have shown relatively improved 
absorption and retention over 24 hours in the body. Such activity 
accumulation and retention in the body is encouraging and therefore merits 
evaluation of these copper chelating agents for possible use as anti-
inflammatory agents. However, these complexes are unlikely to penetrate the 
blood-brain barrier in view of their octanol-water partition coefficients. 
5.5 DERMAL ABSORPTION S1"UDIES 
Although Cu(II) complexes, when administered orally and intravenously do 
increase available copper, it is difficult to move this coordinated metal ion 
through a series of body compartments without protein binding.63 Of all the 
various classical ways of drug administration, percutaneous absorption offers 
the advantage of being a less painful method, and therefore, tolerable to 
patients. However, the percutaneous drug administration relies on the 












The dermal absorption studies on mice were approved by the Research 
Animals Ethics Committee of the University of Cape Town (permission number 
005/039). The procedures for carrying out these experiments were done in 
compliance with the guidelines mentioned in the bio-distribution studies 
(section 5.4). Preparations of solutions of Cu(II) complexes of PrOH, PrOM, 
PrOPr and PCUA were also done the same way as in bio-distribution studies. 
5.5.2 Experimental 
The experimental approach adopted for the dermal absorption experiments 
was similar to that of Scott and co-workers.64 Solutions of Cu(II)(O.OOl mol 
dm-3) - L(0.003 mol dm-3) complexes of PrOH, PrOM, PrOPr and PCUA were 
prepared the same as in the bio-distribution studies. A total of 20 female 
Balb/c mice of age 7-8 weeks weighing 20-23 grams were used in these 
experiments. Groups of four mice per ligand system including control were 
dermally dosed with 0.2 cm3, [ 64Cu]Cu(II)-L solution (containing 6.5 Ilg Cu), 
of 5 ~lCi activity on the enclosed skin of the anterior dorsal side of the test 
animals. 
The application site was prepared by clipping an area of approximately 2 x 2 
cm on the anterior dorsal side of all test animals 15 hours prior to dosing. 
Care was taken to avoid nicking the skin. The animals were anaesthetized 
with saline solution of ketamine/xylazine following clipping and a small tubing 
ring (1.2 cm diameter and 0.5 cm height) was fixed to their backs using 
cyanoacrylate adhesive. On application of dosing solutions to the enclosed 
skin, a polyethylene screen was glued to the top of the ring to prevent access 
to the application site. The mice were kept individually in cages. At the 24 
hour post-dosing time pOint, groups of mice (four at a time) were sacrificed 











cava. Various samples (liver, kidney, ring with application site skin, etc) were 
removed and counted to determine distribution of radioactivity. 
5.5.3 Results and discussion 
The bio-distribution study results for the Cu(II) complexes of PrDH, PrDM, 
PrDPr and PCUA ligands indicate that these complexes survive in vivo. Based 
on these results, it was deemed necessary to perform dermal absorption 
experiments. 
Table 5.4: %Dose unabsorbed and %dose absorbed for the dermal absorption 









.. __ ... 
%dose unabsorbed (ring + enclosed skin) and 
°A d b b d (b d + . ). b k t f o ose a sor e o y urine In rae e s or a given mouse 24 hour 
post-dosing 
Mouse 1 I Mouse 2 I Mouse 3 
95.72 77.77 97.00 
(4.28) (22.23) (3.00) 
95.06 62.89 89.93 
(4.94) (37.11) (10.07) 
82.32 64.05 55.42 
(17.68) (35.95) (44.58) 
91.88 87.66 94.33 
(8.12) (22.34) (5.67) 
77.57 87.55 95.66 
(22.43) (12.45) (4.44) 
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The results for the dermal absorption studies are presented in Table 5.4. The 
most striking feature of these results is their high variability. The variation in 
absorption may be due to a number of reasons. After preparing the 
application site by clipping the area on the anterior dorsal side, the animal 
skin was not cleaned to remove the skin oil. This may have resulted in the 











be the glue which spread over the absorption area and also that the vehicle 
(water) may have not adequately induced absorption. The bio-distribution 
results of the dermally absorbed Cu(II) complexes of PrDH, PrDM, PrDPr and 
PCUA given in Table 5.5 differ from those of the bio-distribution by injection 
through the tail vein. This is not unusual in the sense that it is found that 
bio-distribution depends on a route of administration. Because of the 
variability of the results it is difficult to comment further on these results. 
What is clear however, is that the copper is more widely distributed in the 
body. 
In conclusion, the presently studied ligands are dermally absorbed using 
water as a vehicle. The vehicles such as acetone would do better than water. 
This was demonstrated by Mathew and co-workers65,66 who administered 
approximately 7% of l,3-Diphenyl-l-triazene dermally on rats and mice over 












Table 5.5: Bio-distribution of the dermally absorbed [64Cu]Cu(II) complexes of PrOH, PrOM, PrDPr and PCUA (%dose per organ or gram, 
mean ± std.dev., n=4) 24 hour post-dosing. 




± 0.26 1.95 ± 0.12 1.28 0.34 0.32 0.1 ° 2.25 0.08 1.50 0.2] 
Carcass 2.60 0.11 27.81 ± 12.7 I 1.84 0.81 9.69 ± 5,72 I 0.92 ± 0.56 10.50 14.20 ± 10.2 I 0.89 ± 0.59 
Head 9.2 7.88 ± 2.78 : 2.29 ± 0.79 18.09±8.30 Ii 6.90±3.16 18.63 2.66 13.08±0.91 3.34 ± 0.67 .02 -J 0.20 
Heart 0. II ± 0.02 1.14 0.22 ! 0.37 0,02 i 201 0.11 0.07 ± 0.01 0.62 0.12 ! 0.04±0.02 10,4810.26 10.37 0.07 ii 2.10 0.43 
Intestines 3.29 4.56 14.18 1.73 12.11 ± 1.73 ! ].21 ±0.52 15.99 ± 6.24 I 6.47 ± 2.47 10.83 ± 6.80 ! 4.00 2.59 I 20.92 ± 2.53 ! 6.27 1: 0.70 
0.35 0.05 1.02 to 15 1.84 ± 0.10 ! 3.51f 0.18 I 0.30 0.03 I 0.94 0.11 0.22 0.17 I 0.85 ± 0.60 .74±0.27 13.61 0.63 
') ~ ') 
-"-')- 0.44 2.00 + 0.44 9.96 ± 1.27 12.47 ± 0.51 2.14 ± 0.35 2.04 ± 0.18 1.57 ± 1.00 1.52 ± 1.05 8.48±3.16 13.S0 ± 2.52 
1.17 0.(l2 I (l.S9 n.2·1 I 0.63 ± O.O/l I 3.96 ± l.() I D. 10 ± 0'(l3 I 06.1 ± 0.06 I 0.08 0.()6 I 0.81 0.50 I 0.61 ± 0.12 I .104 ± ().52 
Muscle 
0.06 ± 0.02 I 0.52 ± 0.31 0.56 ± 0.20 I 2.91 ± 0.16 I ().02 0.0 I 0.1 () 0.03 I 0.04 ± 0.02 I 0.52 ±0.53 0.13 0.03 I 0.58 ± 0.27 
Spleen 
(l.()7 ± 0.01 0.77 ± 0.70 I 0.21 ± 0.02 I 2.34 ± 0.58 I 0.03 ± 0.0 I 0.34 ± 0.13 I 0.06 0.03 I 0.79 ± 0.42 I 0.19 ± 0.02 ! 2.11 ± 0.35 
Urine 
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6. GENERAL DISCUSSION AND CONCLUSION 
The role of Cu(ll) in biological systems and processes is well known. 1,2 The 
elevation of Cu(ll) complex species in plasma and synovial fluids of 
rheumatoid arthritis patients is known.3,4 It was also found that a number of 
Cuell) chelates exhibit anti-inflammatory activity. Therefore, several studies 
have been carried out in designing chemically stable, Cu(ll) complexes, for 
use as anti-arthritic agents. 5,6,7 The present study has been designed to 
develop Cu(ll) complexes for their end use as anti-inflammatory human 
pharmaceutical agents. However, the suitable ligand must be able to complex 
Cu(ll) and enhance the transportation across a bio-membrane. 
The present study investigated the solution equilibria of H-'-, Cu2+, Ni2+, Zn2+ 
and Cah with PrOH, PrOM and PrOPr ligands at 25°C and in 0.15 mol dm-3 
CI-(Na+) using glass electrode potentiometry. These ligands have been found 
to take up to three protons in the pH range 2-11. The observed protonation 
constants agree with those of their analogues and the protonation constants 
of PrOH agree with those reported in the Iiterature.8 On the basis of the 
complex formation and deprotonation functions, the models which best 
describe the solution thermodynamics of the M(II)-L systems were chosen. 
Moreover, the reasonably low standard deviations in log0pqr's and Hamilton 
R-factors further confirm the validity of the models used in data analysis. The 
Cu(ll) complexes showed general formation of MLH, ML, MLH-l and MLH-2 
species. The formation equilibria for Ni(II), Zn(II) and Ca(II) show that these 
metal ions form relatively stable complexes with PrOH, PrOM and PrOPr 
However, it is observed that Cu(ll) forms more stable complexes than these 
metal ions. It is also observed that the stability of the M(II)-L complexes is in 
the order M(II)-PrDH > M(II)-PrDM > M(II)-PrDPr. This is due to the different 
basicities of the terminal groups which is in the order -NH2 > -N(CH3h > -Py. 
The calculated selectivity factors indicate that the studied ligands are more 












The elucidation of the chemical structures of Cu(n) complexes of these 
ligands have been determined by using NMR, IR and UV-visible spectroscopy 
as well as molecular mechanics calculations. The results of the protonation 
constants determined by NMR study are in good agreement with values 
obtained from potentiometric studies. The results show that the central 
pyridyl nitrogen and amide nitrogen(s) as well as the terminal amino/pyridyl 
groups coordinate to the metal ion in solution. This is indicated by the 
broadening of the proton resonances and shifting of the NMR signal arising 
from protons attached to neighbouring carbons upon complexation by Cu(n). 
The results from the IR study show a band due to the asymmetric carbonyl 
stretching vibration in these ligands. This band broadens and almost 
disappears at higher pH upon complexation by Cu(U). The involvement of the 
amide nitrogen in the coordination sphere is shown by the increase in 
intensity and shifting of the bands at low frequencies. The UV-visible study 
gave smooth deconvoluted spectra for the individual species of the CuCII)-
PrDH, Cu(II)-PrDM and Cu(Il)-PrDPr systems in support of the potentiometric 
results. The three studied ligands form tetragonally distorted octahedral MLH~: 
and MLH~2 species with Cu(ll) due to the utilization of the ligand field Jahn-
Teller effect. It is indeed worth noting that the incorporation of the central 
pyridyl nitrogen from the pyridine-2,6-dicarboxamide moiety in these ligands 
which is the first one to be coordinated to the metal ion, induces amide 
coordination. Molecular mechanics was used to calculate the strain energies 
(internal) of the different possible geometries for the complexes. A 
comparison of these energies was used to rationalise the different stabilities 
of these complexes. 
ZnCll) and Ca(II) ions, being present in blood plasma in large concentrations 
are regarded as potential competitors of Cu(ll) in vivo. The results of the 
blood plasma simulations show that these metal ions are good competitors of 
Cu(U) for PrDH, PrDM and PCUA in blood plasma whereas PrDPr is relatively 











ligands is in the order PrDPr > PCUA > PrDH > PrDM. The results also show 
that these ligands are better mobilizers of Cu(ll) as compared to the 
previously studied pentadentate donor ligand. The superoxide mimetic 
activity studies show that the ligand system with low Cu(II) mobilizing ability 
has relatively high SOD mimetic activity. The relatively low IC50 of the 
Cu(II)-PrDM system can be interpreted in terms of the possible replacement 
of coordinated water molecule by the superoxide anion radical. The presence 
of the protonated ligand's sites of the MLH~l species should also contribute to 
the dismutation of the superoxide anion radical through hydrogen bonding. 
The ligands PrDH, PrDM, PrDPr and PCUA were designed with the hope that 
the dominant Cu(ll) complex at pH 7.4 would be the neutral [CuLH 2JO 
species. However, the species distribution diagrams from the potentiometric 
results show that the negatively charged MLH~l species dominates at the 
physiological pH (7.4) except for the Cu(II)-PrDPr system which forms rvILH~2 
at this pH. In general, methyl and aryl groups are known to increase the 
lipophilicity of molecules. Having this fact in mind, the present ligands were 
designed. The octanol-water partition coefficients (logPoct/aq) were determined 
as a measure of hydrophobicity. It is observed that 0.43, 0.83, 2.9 and 19% 
of Cu(II)-PrDH, Cu(II)-PrDM, Cu(II)-PCUA and Cu(II)-PrDPr complexes are 
extracted into the organic phase of the octanol-water mixture used as a bio-
phase model. It is indeed observed that the ligand system with bulky groups 
as well as forming neutral complex species has an enhanced extraction into 
the organic phase. 
Based on the aforementioned in vitro results, it was necessary to perform 
biodistribution and dermal absorption experiments. Since the body is a 
dynamic system the biodistribution was measured as a function of time. The 
biodistnbution results revealed an initial rapid clearance of [64Cu]Cu(II)-PrDH, 
[
64Cu]Cu(II)-PrDM, [64CU]Cu(II)-PCUA and [64Cu]Cu(II)-PrDPr complexes from 
the blood and initial rapid and high uptake by the liver. The high uptake in 
the liver is due to the fact that copper storing and metabolism occur in this 











Jackson and co-workers6 for [64Cu]Cu(II) complexes of polyamino ligands, the 
presently investigated complexes were found to be significantly retained by 
most of the organs. The aforementioned polyamino systems were observed to 
be rapidly excreted unchanged via the renal route because they were too 
hydrophilic and stable such that the complex was excreted intact in the urine. 
Nomkoko and co-workers7,9,10 also studied poly(amine)amide ligands which 
showed that some of their systems were reasonably retained in the body 
under the same conditions. Indeed the presently studied ligands have shown 
relatively improved absorption and retention over 24 hours in the body. Such 
activity accumulation and retention in the body is encouraging and therefore 
merits evaluation of these copper chelating agents for possible use as anti-
inflammatory agents. Dermal absorption results also showed that at least 5 
%dose of the applied dose on the enclosed skin was absorbed over a period 
of 24 hours. Therefore, these ligands' systems seem to be dermally absorbed 
using water as a vehicle. 
The overall results in this study are encouraging and merit further evaluation 
for the use of Cu(II) complexes in chemotherapy and diagnosis. It is hoped 
that this study has contributed to the knowledge and understanding of some 
factors involved in the development of copper chelating agents for the 
alleviation of inflammation associated with RA. The proposed ligands for 
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